

Center for Vaccine  
Ethics and Policy



**Vaccines and Global Health: The Week in Review**  
**18 November 2023 :: Issue 727**  
**Center for Vaccine Ethics & Policy (CVEP)**

*This weekly digest targets news, events, announcements, articles and research in the vaccine and global health ethics and policy space and is aggregated from key governmental, NGO, international organization and industry sources, key peer-reviewed journals, and other media channels. This summary proceeds from the broad base of themes and issues monitored by the Center for Vaccine Ethics & Policy in its work: it is not intended to be exhaustive in its coverage.*

*Vaccines and Global Health: The Week in Review is published as a PDF and scheduled for release each Saturday [U.S.] at midnight [0000 GMT-5]. The PDF is posted at <https://centerforvaccineethicsandpolicy.net>. This blog allows full text searching of over 27,000 entries.*

*Comments and suggestions should be directed to*

*David R. Curry, MS*

*Editor and*

*Executive Director*

*Center for Vaccine Ethics & Policy*

*[david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)*

***Request email delivery of the pdf:*** *If you would like to receive the PDF of each edition via email [Constant Contact], please send your request to [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org).*

***Support this knowledge-sharing service:*** *Your financial support helps us cover our costs and to address a current shortfall in our annual operating budget. Click [here](#) to donate and thank you in advance for your contribution.*

***Contents [click to move among sections]***

*:: [Milestones, Perspectives](#)*

*:: [WHO](#)*

*:: [Organization Announcements](#)*

*:: [Journal Watch](#)*

*:: [Pre-Print Servers](#)*

*:: [Think Tanks](#)*

## *Milestones, Perspectives*



### [Progress Toward Measles Elimination — Worldwide, 2000–2022](#)

MMWR Morb Mortal Wkly Rep. November 17, 2023 / 72(46);1262–1268

Anna A. Minta, MD1; Matt Ferrari, PhD2; Sebastien Antoni, MPH1; Allison Portnoy, ScD3; Alyssa Sbarra, MPH4; Brian Lambert2; Cynthia Hatcher, MPH5; Christopher H. Hsu, MD, PhD5; Lee Lee Ho, MPH1; Claudia Steulet, MPH1; Marta Gacic-Dobo, MSc1; Paul A. Rota, PhD6; Mick N. Mulders, PhD1; Anindya Sekhar Bose, MD1; William Perea Caro, MD1; Patrick O'Connor, MD1; Natasha S. Crowcroft, MD1 ([View author affiliations](#))

#### **Summary**

*What is already known about this topic?*

Global coverage with measles-containing vaccine (MCV) declined during the COVID-19 pandemic to the lowest levels since 2008, and measles surveillance was suboptimal.

*What is added by this report?*

During 2000–2022, estimated measles vaccination prevented approximately 57 million deaths worldwide. **However, millions of children missed vaccinations during the COVID-19 pandemic, resulting in an 18% increase in estimated measles cases and a 43% increase in estimated measles deaths in 2022 compared with 2021. Large or disruptive outbreaks were reported in 37 countries.** Measles surveillance remains suboptimal.

*What are the implications for public health practice?*

To continue progress toward measles elimination, all children should receive 2 MCV doses to address pandemic-related immunity gaps and measles surveillance should be strengthened.

#### **Abstract**

Measles is a highly contagious, vaccine-preventable disease that requires high population immunity for transmission to be interrupted. All six World Health Organization regions have committed to eliminating measles; however, no region has achieved and sustained measles elimination. This report describes measles elimination progress during 2000–2022. During 2000–2019, estimated coverage worldwide with the first dose of measles-containing vaccine (MCV) increased from 72% to 86%, then declined to 81% in 2021 during the COVID-19 pandemic, representing the lowest coverage since 2008. In 2022, first-dose MCV coverage increased to 83%. Only one half (72) of 144 countries reporting measles cases achieved the measles surveillance indicator target of two or more discarded cases per 100,000 population in 2022. During 2021–2022, estimated measles cases increased 18%, from 7,802,000 to 9,232,300, and the number of countries experiencing large or disruptive outbreaks increased from 22 to 37. Estimated measles deaths increased 43% during 2021–2022, from 95,000 to 136,200. Nonetheless, an estimated 57 million measles deaths were averted by vaccination during 2000–2022. In 2022, measles vaccination coverage and global surveillance showed some recovery from the COVID-19 pandemic setbacks; however, coverage declined in low-income countries, and globally, years of suboptimal immunization coverage left millions of children unprotected. Urgent reversal of coverage setbacks experienced during the COVID-19 pandemic can be accomplished by renewing efforts to vaccinate all children with 2 MCV doses and strengthening surveillance, thereby preventing outbreaks and accelerating progress toward measles elimination.



## [Global measles threat continues to grow as another year passes with millions of children unvaccinated](#)

November 16, 2023

**Following years of declines in measles vaccination coverage, measles cases in 2022 have increased by 18%, and deaths have increased by 43% globally (compared to 2021).** This takes the estimated number of measles cases to 9 million and deaths to 136,000 – mostly among children – according to a [new report](#) from the World Health Organization (WHO) and the U.S. Centers for Disease Control and Prevention (CDC).

**Measles continues to pose a relentlessly increasing threat to children. In 2022, 37 countries experienced large or disruptive outbreaks compared with 22 countries in 2021. Of the countries experiencing outbreaks, 28 were in the WHO Region for Africa, six in the Eastern Mediterranean, two in Southeast Asia, and one in the European Region.**

“The increase in measles outbreaks and deaths is staggering, but unfortunately, not unexpected given the declining vaccination rates we’ve seen in the past few years,” said John Vertefeuille, director of CDC’s Global Immunization Division. “Measles cases anywhere pose a risk to all countries and communities where people are under-vaccinated. Urgent, targeted efforts are critical to prevent measles disease and deaths.”

**...Low-income countries, where the risk of death from measles is highest, continue to have the lowest vaccination rates at only 66%; a rate that shows no recovery at all from the backsliding during the pandemic.** Of the 22 million children who missed their first measles vaccine dose in 2022, over half live in just 10 countries: Angola, Brazil, Democratic Republic of the Congo, Ethiopia, India, Indonesia, Madagascar, Nigeria, Pakistan, and Philippines

“The lack of recovery in measles vaccine coverage in low-income countries following the pandemic is an alarm bell for action. Measles is called the inequity virus for good reason. It is the disease that will find and attack those who aren’t protected,” said Kate O’Brien, WHO Director for Immunization, Vaccine and Biologicals. “Children everywhere have the right to be protected by the lifesaving measles vaccine, no matter where they live. ”

**CDC and WHO urge countries to find and vaccinate all children against measles and other vaccine-preventable diseases and encourage global stakeholders to aid countries to vaccinate their most vulnerable communities.** In addition, to help prevent outbreaks, all global health partners at the global, regional, national, and local levels must invest in robust surveillance systems and outbreak response capacity to rapidly detect and respond to outbreaks.

CDC and WHO are founding members of the [Measles & Rubella Partnership](#) (M&RP), a global initiative to stop measles and rubella. Under the umbrella of [Immunization Agenda 2030](#) and guided by the [Measles and Rubella Strategic Framework 2030](#), M&RP’s mission includes addressing the decline in national vaccination coverage, hastening COVID-19 pandemic recovery and accelerating progress towards creating a world free of measles and rubella. The partnership also includes [American Red Cross](#), [Bill & Melinda Gates Foundation](#), [Gavi](#), [the Vaccine Alliance](#), [United Nations Foundation](#), and [UNICEF](#).

.....  
.....

## ***Rand Report***

### **Data collection and sharing for pathogen surveillance: Making sense of a fragmented global system**

Nov 15, 2023

Sarah Parkinson, Jessica Dawney, Avery Adams, Ben Senator

PDF: [https://www.rand.org/content/dam/rand/pubs/research\\_reports/RRA2700/RRA2788-1/RAND\\_RRA2788-1.pdf](https://www.rand.org/content/dam/rand/pubs/research_reports/RRA2700/RRA2788-1/RAND_RRA2788-1.pdf)

#### *Overview*

RAND Europe was commissioned by the Novo Nordisk Foundation to conduct a study on pathogen surveillance and current initiatives. The study aims to provide an overview of the pathogen surveillance space internationally and the stakeholders involved, as well as to understand the strengths and weaknesses of different initiatives, the challenges of pathogen surveillance and how they have been addressed, and how data has been used to inform public health decision making. To do this, a scoping review of pathogen surveillance initiatives was conducted, and ten case studies were developed and selected for further review following a workshop attended by the Novo Nordisk Foundation and RAND Europe study team. Interviews were conducted with individuals involved in pathogen surveillance initiatives to gather additional information to develop case studies, and expert interviews addressed gaps in the pathogen surveillance space and models that would be helpful in filling these gaps.

#### *Key Findings*

- The pathogen surveillance space is highly fragmented.
- Capacity constraints and logistical challenges, particularly in low-resource settings, limit the availability of data for surveillance.
- The ability to conduct integrated and real-time surveillance is critical to public health decision making.

#### *Recommendations*

- There is a need to build distributed and sustainable capacity.
- More harmonised approaches and methods are needed to improve integration between data streams and reduce siloed data.
- There is potential to use artificial intelligence (AI) and data science techniques.
- Common approaches for pathogen surveillance would need to balance being simple enough to implement and having the sophistication to capture granular, complex information.



### **The socio-economic value of adult immunization (OHE)**

*OHE External study* EE136 16 Nov 2023

This study was commissioned by IFPMA.

PDF: [https://www.ifpma.org/wp-content/uploads/2023/11/231116\\_Socio\\_Economic\\_Value\\_Adult\\_Immunization\\_OHE-1.pdf](https://www.ifpma.org/wp-content/uploads/2023/11/231116_Socio_Economic_Value_Adult_Immunization_OHE-1.pdf)

This study by the Office of Health Economics (OHE) synthesizes existing evidence for the broad, socio-economic value of adult immunization programs, focusing on influenza, pneumococcal, herpes zoster (HZ), and respiratory syncytial virus (RSV) programs in ten countries (Australia, Brazil, France, Germany, Italy, Japan, Poland, South Africa, Thailand, United States).

In a forthcoming publication, OHE will present the results of a cost-benefit analysis to quantify the societal return on investment for vaccination programs in these countries.

# Results: Availability of evidence

The heatmap table below visualises the available evidence on the value of four focus vaccines, for each element of the value framework:

**TABLE 1: PERCENTAGE OF SAMPLE COUNTRIES FOR WHICH LOCAL EVIDENCE ON THE VALUE ELEMENT HAS BEEN PUBLISHED\***

Value domain	Population health				Healthcare system		Society				
	Impact on quality of life of vaccinated	Impact on mortality of vaccinated	Impact on quality of life of carers	Transmission value	Cost offsets to healthcare system	Value to other interventions	Impact on productivity of vaccinated	Impact on carer productivity	Social equity value	AMR prevention value **	Macroeconomic effects
Influenza	100	100		50	80		60	20		10	
Pneumo-coccal	60	50		30	60		40	10	10		
RSV	60	10		10							
HZ	70	30			40		30	10			

Key: percentage of sample countries for which relevant evidence identified				
100%	70-90%	40-60%	10-30%	No evidence

\* evidence from these sample countries may not be representative of the availability of global evidence on each value element; \*\* AMR = Antimicrobial resistance

- Evidence availability is greatest for the 'narrow' benefits, including quality of life and mortality benefits to vaccinated individuals and cost-offsets to healthcare systems.
- The most well-recognized 'broader' value elements are productivity effects and transmission.
- A nascent evidence base also shows some positive effects with respect to social equity value and value in preventing antimicrobial resistance.

## Conclusion

- The evidence found supports the critical role of optimising adult immunisation programmes in addressing major health and societal challenges while aligning with critical global agendas such as the UN Sustainable Development Goals (SDGs), the WHO Immunisation Agenda 2030 (IA2030), and the UN Decade of Health Ageing.
- However, the research also clearly shows that many dimensions of the value of adult immunisation programmes are currently underrepresented in the academic literature.

- Without such evidence, the full value of vaccination programmes is likely underestimated by policy -and decision-makers, riskingsuboptimal investment decisions.



## **Addressing Adult Immunisation Inequity and Improving the Uptake Rates of Adult Vaccination Among Older People**

IFA [International Federation on Aging] – (c)Vaccines4Life

September 2023 :: 11 pages

PDF: <https://www.vaccines4life.com/download/30753/?tmstv=1700231124>

### *Overview*

...This publication underscores the importance and urgency of ensuring equitable access to vaccinations for all older adults through the sustained and meaningful integration of a life course approach to immunization and highlights the IFA's continued commitment to ensuring that the rights and choices of older adults are respected and protected...

### ***Calls to action***

- Prioritize immunisation throughout life as a key pillar of expanded prevention strategies that can help facilitate healthy ageing;
- Increase investment in infrastructure to ensure access to vaccination for those at high-risk of VPDs including older adults and individuals with chronic conditions;
- Implement a life course approach to immunisation through a comprehensive national immunisation plan that respects the rights of all people regardless of age;
- Identify and act upon modifiable barriers-simplification of pathways, expansion of vaccinators, and target specific populations to reduce inequities;
- Improve surveillance and monitoring systems to ensure there is capacity to identify at-risk populations, adopt and recommend specific vaccines, and monitor and evaluate uptake rates;
- Develop and deliver effective immunisation campaigns that translate evidence into action to improve the uptake rates of adult vaccination. Campaigns should be tailored to the local context and provide reliable, up-to-date, evidence-informed information that is accessible through multiple channels;
- Increase public confidence in vaccines by driving health-seeking behaviour and communicating the value of immunisation through trusted stakeholders including health care professionals

### ***Conclusion***

Addressing adult immunisation inequity and improving the uptake rates of adult vaccination among older people requires a deep understanding of the evidence, the policy gaps and the unequivocal need to use a sustained multistakeholder approach to drive change in the context the Immunisation Agenda 2030 and the UN Decade of Healthy Ageing.

The COVID-19 pandemic demonstrated the ability of all governments to develop, implement, and monitor immunisation policies for the health of all citizens and especially those most at-risk of serious complications and death. These lessons learned in the direst of circumstances must be leveraged to ensure that older adults have access to routine vaccinations (e.g., influenza, pneumococcal pneumonia, pertussis, and shingles) in a timely and affordable manner.

This policy brief has highlighted the importance of ensuring that governments and policymakers consider the unique situational contexts, and the increased risk certain environments pose to those most at-risk when developing vaccine-related policies.



## **Progress report on the United Nations Decade of Healthy Ageing, 2021-2023**

17 November 2023

## Overview

The purpose of this report is to: assess the extent of progress made in the first phase of implementation of the UN Decade of Healthy Ageing, from 2021 to mid-2023; present contributions to the Decade being made by stakeholder groups, including Member States, UN agencies, civil society, academia, the private sector, community groups and older people themselves; and inspire and motivate stakeholders to collaborate in their continued efforts to implement the Decade at country level and scale up interventions to ensure healthy ageing.



## Gaza

### [WHO leads very high-risk joint humanitarian mission to Al-Shifa Hospital in Gaza](#)

18 November 2023 –

Earlier today, a joint UN humanitarian assessment team, led by WHO accessed Al-Shifa Hospital in northern Gaza to assess the situation on the ground and conduct a rapid situational analysis, assess medical priorities, and establish logistics options for further missions. The team included public health experts, logistics officers, and security staff from OCHA, UNDSS, UNMAS/UNOPS, UNRWA and WHO.

The mission was deconflicted with the Israel Defense Forces (IDF) to ensure safe passage along the agreed route. However, this was a high-risk operation in an active conflict zone, with heavy fighting ongoing in close proximity to the hospital...

...Given the current state of the hospital, which is no longer operational or admitting new patients, the team was requested to evacuate health workers and patients to other facilities. WHO and partners are urgently developing plans for the immediate evacuation of the remaining patients, staff and their families. Over the next 24–72 hours, pending guarantees of safe passage by parties to the conflict, additional missions are being arranged to urgently transport patients from Al-Shifa to Nasser Medical Complex and European Gaza Hospital in the south of Gaza. However, these hospitals are already working beyond capacity, and new referrals from Al-Shifa Hospital will further strain overburdened health staff and resources.

WHO is deeply concerned about the safety and health needs of patients, health workers and internally displaced people sheltering at the few remaining partially functional hospitals in the north, which are facing risk of closure due to a lack of fuel, water, medical supplies, food, and the intense hostilities. Immediate efforts must be made to restore the functionality of Al-Shifa and all other hospitals to provide urgently needed health services in Gaza.

WHO reiterates its plea for collective efforts to bring an end to the hostilities and humanitarian catastrophe in Gaza. We call for an immediate ceasefire, the sustained flow of humanitarian assistance at scale, unhindered humanitarian access to all of those in need, the unconditional release of all hostages, and the cessation of attacks on health care and other vital infrastructure. The extreme suffering of the people of Gaza demands that we respond immediately and concretely with humanity and compassion.



## Polio – PHEIC

### Polio this week as of 15 Nov 2023 - GPEI

*Headlines [Selected]*

*Summary of new polioviruses this week, cases and positive environmental isolates:*

- Afghanistan: seven WPV1-positive environmental samples
- Pakistan: one WPV1 case and nine positive environmental samples
- Algeria: one cVDPV2-positive environmental sample
- Chad: five cVDPV2 cases
- Côte d'Ivoire: three cVDPV2-positive environmental samples
- DR Congo: four cVDPV1 cases, four cVDPV2 cases and five cVDPV2 positive environmental samples
- Guinea: five cVDPV2 cases and one positive environmental sample
- Kenya: three cVDPV2-positive environmental samples
- Nigeria: eight cVDPV2 cases and nine positive environmental samples
- Somalia: one cVDPV2 case and one positive environmental sample
- Tanzania: one cVDPV2-positive environmental sample
- Zimbabwe: two cVDPV2-positive environmental samples

.....  
.....

## Coronavirus [COVID-19]

<https://www.who.int/emergencies/diseases/novel-coronavirus-2019>

### Numbers at a glance

*Last update: 16 Nov 2023*

**Confirmed cases** :: 772 011 164

**Confirmed deaths** :: 6 979 786

**Vaccine doses administered:** 13 534 602 932

.....

### *Our World in Data*

**Coronavirus (COVID-19) Vaccinations** [Accessed 18 Nov 2023]

:: 70.6% of the world population has received at least one dose of a COVID-19 vaccine.

:: 13.53 billion doses have been administered globally, and 9,717 are now administered each day.

:: 32.8% of people in low-income countries have received at least one dose.

.....  
.....

### ***Contents [click to move among sections]***

:: *Milestones, Perspectives*

:: *WHO*

:: *Organization Announcements*

:: *Journal Watch*

:: *Pre-Print Servers*

.....  
.....



## **WHO & Regional Offices** [to 18 Nov 2023]

<https://www.who.int/news>

*Selected News/Announcements/Statements*

18 November 2023 Statement

[WHO leads very high-risk joint humanitarian mission to Al-Shifa Hospital in Gaza](#)

17 November 2023 Departmental news

[World AMR Awareness Week: preventing antimicrobial resistance together](#)

17 November 2023 News release

[Global partners cheer progress towards eliminating cervical cancer and underline challenges](#)

17 November 2023 Departmental news

[Second World Local Production Forum Recommendations](#)

16 November 2023 Joint News Release

[Global measles threat continues to grow as another year passes with millions of children unvaccinated](#)

16 November 2023 Departmental news

[Message by the Director of the Department of Immunization, Vaccines and Biologicals at WHO - October 2023](#)

14 November 2023 Departmental news

[WHO launches new 5-year roadmap to prevent and treat TB in children and adolescents](#)

.....

## **WHO Regional Offices**

*Selected Press Releases, Announcements*

### **WHO African Region**

No new digest content identified.

### **WHO Region of the Americas** PAHO

:: 17 Nov 2023

[Improving Child and Adolescent Health in the Americas with a Focus on Equity: PAHO Director](#)

Washington, DC, November 17, 2023 (PAHO)- Following the impact of the COVID-19 pandemic in the Americas, there is a need to prioritize and improve child and adolescent health and development in countries in the region, the Director of the Pan American Health Organization (PAHO), Dr. Jarbas Barbosa said in an event today, emphasizing the importance...

### **WHO South-East Asia Region SEARO**

:: 18 November 2023 Statement

[World Antimicrobial Awareness Week](#)

:: 17 November 2023 Statement

[Cervical Cancer Elimination Day of Action 202](#)

### **WHO European Region EURO**

:: 10 November 2023 News release

[WHO/Europe's Novel Medicines Platform launches solidarity-focused working group to transform patient access to medicines](#)

## **WHO Eastern Mediterranean Region EMRO**

:: [Conflict in Israel and the occupied Palestinian territory](#)

:: [WHO leads very high-risk joint humanitarian mission to Al-Shifa Hospital in Gaza](#) 18 November 2023

## **WHO Western Pacific Region**

:: 15 November 2023

[Building support for climate action: WHO launches parliamentary briefs on climate change and the environment](#)

:: 14 November 2023

[Cambodia harnesses youth innovation to combat antimicrobial resistance](#)

.....

## **WHO - Emergency situation reports**

17 November 2023

[WHO's Operational Update on Health Emergencies - October 2023](#)

*Overview*

In this edition of WHO's Operational Update on Health Emergencies, highlights of country-level actions and WHO support to countries include:

- Ensuring access to lifesaving essential health care services in the occupied Palestinian territory
- Israel's health system responds to the October 2023 attacks
- WHO provides emergency support to the Armenia refugee response
- Supporting the response to the earthquakes in Herat, Afghanistan...

.....

## **Disease Outbreak News (DONs)**

*Latest WHO Disease Outbreak News (DONs), providing information on confirmed acute public health events or potential events of concern.*

*No new DONs reported.*

.....

## **Weekly Epidemiological Record**

<https://www.who.int/publications/journals/weekly-epidemiological-record>

Vol. 98, No. 46, pp. 583–598 17 November 2023

PDF: <https://iris.who.int/bitstream/handle/10665/374186/WER9846-eng-fre.pdf>

*Contents*

583 WHO's Health Emergencies Programme: acute emergencies monthly summary – October 2023

587 Progress towards regional measles elimination – worldwide, 2000–2022

.....

## **New WHO Publications**

<https://www.who.int/publications/i>

*Selected*

17 November 2023

[Progress report on the United Nations Decade of Healthy Ageing, 2021-2023](#)

*Overview*

The purpose of this report is to: assess the extent of progress made in the first phase of implementation of the UN Decade of Healthy Ageing, from 2021 to mid-2023; present contributions to the Decade being made by stakeholder groups, including Member States, UN agencies, civil society, academia, the private sector, community groups and older people themselves; and inspire and motivate stakeholders to collaborate in their continued efforts to implement the Decade at country level and scale up interventions to ensure healthy ageing.

16 November 2023

[Mid-term evaluation of the Global Strategy to Eliminate Yellow Fever Epidemics \(EYE\) 2017–2026: Annexes](#)

15 November 2023

[Global competency framework for regulators of medicines](#)

*Overview*

The Global Competency Framework for Regulators of Medicines (GCF) provides a framework for best practices and general considerations aimed at harmonizing workforce development efforts for the regulation of medicines by establishing an internationally accepted set of organizational and role-specific competencies.

The GCF provides recommendations for the competency requirements for regulators across the identified regulatory functions and maturity levels, as defined by the Global Benchmarking Tool (GBT) that is used to guide countries through gap analysis and systematic institutional development. The maturity model in the GBT represents a tool for a National Regulatory Authority's (NRA) development and a continuum of the NRA's capabilities in performing regulatory functions. Thus, the GCF allows competency modelling by individual NRAs across the maturity levels, particularly maturity levels 1 to 3, aligning individual capabilities with the organizational strategy and business processes.

15 November 2023

[Catalogue of mutations in Mycobacterium tuberculosis complex and their association with drug resistance,...](#)

14 November 2023

[Operational guidance for evaluating and publicly designating regulatory authorities as WHO-listed...](#)

14 November 2023

[Manual for the performance evaluation of regulatory authorities seeking the designation as WHO-listed...](#)

14 November 2023

[Managing epidemics: key facts about major deadly diseases, 2nd edition](#)

*Overview*

Epidemics and pandemics of infectious diseases are occurring more often, and spreading faster and further than ever, in many different regions of the world. The background factors of this threat are biological, environmental and lifestyle changes, among others. A potentially fatal combination of newly-discovered diseases, and the re-emergence of many long-established ones, demands urgent responses in all countries. Planning and preparation for epidemic prevention and control are essential. The purpose of the Managing epidemics handbook is to provide expert guidance on those responses. Building on the first edition, the second edition provides concise and basic up-to-date knowledge with which public health officials can respond effectively and rapidly at the very start of an outbreak. Part I of the handbook provides insights on epidemics of the 21st century and offers context on the upsurge of recent epidemics. Part II has been updated and offers 10 key facts about 19 deadly diseases including tips on the interventions required to respond. Part III presents various

Tool boxes that summarize guidance on several important topics. The handbook focuses on practical and indispensable things to know about infectious diseases that are most important for national, political and operational decision-makers; it also links readers to more exhaustive WHO guidance.

14 November 2023

[Roadmap towards ending TB in children and adolescents, 3rd ed](#)



## **USA – HHS, FDA, CDC**

### **HHS**

#### *News*

#### **[The Biden-Harris Administration Takes Action to Improve Health and Wellbeing by Addressing Social Determinants of Health](#)**

November 16, 2023 News Release

The White House and the U.S. Department of Health and Human Services (HHS), through the Centers for Medicare & Medicaid Services (CMS), is releasing several resources to help support federal agencies, states, local and tribal governments to better coordinate health care, public health, and social services. Specifically, the White House is releasing the first ever [U.S. Playbook to Address Social Determinants of Health - PDF](#). To accompany this, the Department of Health and Human Services (HHS) is releasing a [Call to Action to Address Health Related Social Needs](#), and a [Medicaid and CHIP Health-Related Social Needs Framework - PDF](#). This builds on the Administration's work to advance health equity by acknowledging that peoples' social and economic conditions play an important role in their health and wellbeing...

#### **[HHS Establishes Secretary's Advisory Committee on Long COVID](#)**

November 16, 2023 News Release

*Committee will help advise on research and innovation in the whole-of-government response to the longer-term impacts of COVID-19, Inviting nominations.*

Today, the U.S. Department of Health and Human Services (HHS) announces the establishment of the Secretary's Advisory Committee on Long COVID and invites nominations for the Committee. This Committee is called for in the [National Research Action Plan on Long COVID - PDF](#), published in April of 2022 to make recommendations on research and innovation in the whole-of-government response to the longer-term impacts of COVID-19. This Committee will bring perspectives from outside the government to help inform action on Long COVID and associated conditions, with a focus on health equity...

#### **[Readout of HHS Secretary Becerra's Meeting with National Public Health Leaders on Vaccines for COVID, flu and RSV](#)**

November 15, 2023 News Release

*Secretary Becerra reiterated HHS commitment to continued partnership with public health leaders and advocates to encourage communities to receive updated COVID-19, flu, and RSV vaccines this holiday season.*

### **FDA**

#### *Press Announcements*

*No new meetings scheduled.*

### **FDA VRBPAC**

[Advisory Committee Calendar](#)

*No new meetings scheduled.*

### **CDC/ACIP [U.S.] [to 18 Nov 2023]**

<http://www.cdc.gov/media/index.html>

*Latest News Releases*

#### **[Global measles threat continues to grow as another year passes with millions of children unvaccinated](#)**

November 16, 2023 Following years of declines in measles vaccination coverage, measles cases in 2022 have increased by 18%, and deaths have increased by 43% globally (compared to 2021).

#### **[CDC and FDA Expedite the Availability of Additional Doses of New RSV Immunization for Infants](#)**

November 16, 2023 Today, CDC announced the release of more than 77,000 additional doses of Beyfortus™ (nirsevimab-alip (100 mg), a long-acting monoclonal antibody designed to protect infants against severe respiratory syncytial virus (RSV) disease.

### **ACIP Meetings**

*Next ACIP Meeting*

*No new meetings scheduled.*

### **MMWR Weekly**

<https://www.cdc.gov/mmwr/index2023.html>

#### **November 17, 2023 / No. 46**

[PDF of this issue](#)

- [Progress Toward Measles Elimination — Worldwide, 2000–2022](#)
- [Vital Signs: Missed Opportunities for Preventing Congenital Syphilis — United States, 2022](#)
- [Notes from the Field: Surveillance of Silicosis Using Electronic Case Reporting — California, December 2022–July 2023](#)
- [Notes from the Field: A Cluster of Multi-Strain Invasive Pneumococcal Disease Among Persons Experiencing Homelessness and Use of Pneumococcal Conjugate Vaccine — El Paso County, Colorado, 2022](#)

-

.....

.....

### **Europe**

#### **European Medicines Agency [EMA]**

[https://www.ema.europa.eu/en/search/search/ema\\_editorial\\_content/ema\\_news?sort=field\\_ema\\_computed\\_date\\_field&order=desc](https://www.ema.europa.eu/en/search/search/ema_editorial_content/ema_news?sort=field_ema_computed_date_field&order=desc)

*News & Press Releases*

*No new digest content identified.*

.....

#### **European Centre for Disease Prevention and Control**

<https://www.ecdc.europa.eu/en>

*News/Updates/Reports/Publications [Selected]*

*News*

#### **[Reducing antimicrobial resistance: is the EU progressing towards the 2030 targets?](#)**

Press release - 17 Nov 2023

*Scientific and technical publications*

**[External quality assessment \(EQA\) of the performance of laboratories participating in the European Antimicrobial Resistance Surveillance Network \(EARS-Net\), 2022](#)**

External quality assessment - 17 Nov 2023

*Scientific and technical publications*

**[Surveillance of antimicrobial resistance in Europe, 2022 data](#)**

Surveillance report - 17 Nov 2023

*Scientific and technical publications*

**[Brief: Antimicrobial resistance targets - how can we reach them by 2030?](#)**

Communication toolkit - 17 Nov 2023

*Scientific and technical publications*

**[Antimicrobial consumption in the EU/EEA \(ESAC-Net\) - Annual Epidemiological Report for 2022](#)**

Surveillance report - 17 Nov 2023

.....  
.....

**Africa CDC** [to 18 Nov 2023]

<http://www.africacdc.org/>

*Press Releases, Statements [Selected]*

**[Zimbabwe Hosts the World AMR Awareness Week 2023, 18-24th November 2023](#)**

17 November 2023

.....  
.....

**China CDC**

<http://www.chinacdc.cn/en/>

**National Health Commission of the People's Republic of China** [to 18 Nov 2023]

<http://en.nhc.gov.cn/>

*News*

*No new digest content identified.*

**National Medical Products Administration – PRC** [to 18 Nov 2023]

<http://english.nmpa.gov.cn/>

*News*

*No new digest content identified.*

**China CDC Weekly Reports: Current Volume (5)**

**2023-11-17 / No. 46 WORLD ANTIBIOTIC AWARENESS WEEK ISSUE**

[View PDF of this issue](#)

- [Preplanned Studies: Occurrence and Removal of Antibiotic Resistance in Nationwide Hospital Wastewater Deciphered by Metagenomics Approach — China, 2018–2022](#)
- [Methods and Applications: Effect of CeO<sub>2</sub> Nanoparticles on the Spread of Antibiotic Resistance in a Reclaimed Water-Soil-Radish System — Shenzhen City, Guangdong Province, China, April 2023](#)
- [Notifiable Infectious Diseases Reports: Reported Cases and Deaths of National Notifiable Infectious Diseases — China, September 2023\\*](#)

- **Commentary: Mitigating Antibiotic Resistance Emissions in the Pharmaceutical Industry: Global Governance and Available Techniques**

We highlight the paramount importance of pretreatment processes preceding the biological treatment of antibiotic manufacturing wastewater as a strategy to curb the escalation of antibiotic resistance. In an effort to curtail the advancement of antimicrobial resistance (AMR) in antibiotic production in China, a comprehensive array of technical and regulatory initiatives have been implemented. These measures offer valuable insights that could inform and enhance global AMR containment strategies. Looking ahead, there is a pressing need to form an interdisciplinary team tasked with refining antibiotic emission standards and tailoring environmental engineering practices for the pharmaceutical sector...



***Contents [click to move among sections]***

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)



***Organization Announcements***

**Paul G. Allen Frontiers Group** [to 18 Nov 2023]

<https://alleninstitute.org/news-press/>

*News*

*No new digest content identified.*

**BMGF - Gates Foundation** [to 18 Nov 2023]

<https://www.gatesfoundation.org/ideas/media-center>

*Press Releases and Statements*

*No new digest content identified.*

**Bill & Melinda Gates Medical Research Institute** [to 18 Nov 2023]

<https://www.gatesmri.org/news>

*The Bill & Melinda Gates Medical Research Institute is a non-profit biotech organization. Our mission is to develop products to fight malaria, tuberculosis, and diarrheal diseases—three major causes of mortality, poverty, and inequality in developing countries. The world has unprecedented scientific tools at its disposal; now is the time to use them to save the lives of the world's poorest people*

*News: Articles and Publications*

*No new digest content identified.*

**CARB-X** [to 18 Nov 2023]

<https://carb-x.org/>

*News*

*No new digest content identified.*

**CEPI – Coalition for Epidemic Preparedness Innovations** [to 18 Nov 2023]

<http://cepi.net/>

*Latest News*

**[The Viral Most Wanted: The Arenavirus Family](#)**

The Arenavirus family includes some of the most lethal haemorrhagic fevers known. All its prime suspects can cause life-threatening disease and death.

15 Nov 2023

**CIOMS – COUNCIL FOR INTERNATIONAL ORGANIZATIONS OF MEDICAL SCIENCES** [to 18 Nov 2023]

<https://cioms.ch/>

*News; Publications; Events*

*No new digest content identified.*

**DARPA – Defense Advanced Research Projects Agency [U.S.]** [to 18 Nov 2023]

<https://www.darpa.mil/news>

*News*

*No new digest content identified.*

**Duke Global Health Innovation Center** [to 18 Nov 2023]

<https://dukeghic.org/>

*News*

*No new digest content identified.*

**EDCTP** [to 18 Nov 2023]

<http://www.edctp.org/>

*The European & Developing Countries Clinical Trials Partnership (EDCTP) aims to accelerate the development of new or improved drugs, vaccines, microbicides and diagnostics against HIV/AIDS, tuberculosis and malaria as well as other poverty-related and neglected infectious diseases in sub-Saharan Africa, with a focus on phase II and III clinical trials*

*News*

*No new digest content identified.*

**Emory Vaccine Center** [to 18 Nov 2023]

<http://www.vaccines.emory.edu/>

*Vaccine Center News*

*No new digest content identified.*

**European Vaccine Initiative** [to 18 Nov 2023]

<http://www.euvaccine.eu/>

*Latest News, Events*

**[Igniting Innovation: 2023 EU-China Vaccine Collaboration Forum highlights global synergies](#)**



November 2024 In the heart of Wuxi, China, from November 3-4, 2023, the pulse of innovation echoed at the 2023 EU-

**Evidence Aid** [to 18 Nov 2023]

*Evidence Aid aims to save lives and livelihoods in disasters by providing decision-makers with the best available evidence and by championing its use.*

<http://www.evidenceaid.org/>

*Resources [Selected]*

*No new digest content identified.*

**Fondation Merieux** [to 18 Nov 2023]

<http://www.fondation-merieux.org/>

*News, Events*

*No new digest content identified.*

**Gavi** [to 18 Nov 2023]

<https://www.gavi.org/>

*News Releases*

**[Increase in Measles Deaths Demands Urgent Action to Save Lives](#)**

16 November 2023 – More children died from measles in 2022 than 2021, according to a new report released today by the World Health Organization (WHO) and the U.S. Centers for Disease Control and Prevention (CDC). The data serve as an urgent call to action—placing renewed attention on the importance of life-saving vaccine...

**GE2P2 Global Foundation** [to 18 Nov 2023]

[www.ge2p2.org](http://www.ge2p2.org)

*News/Analysis/Publications-Digests/Statements*

:: [Vaccines and Global Health: The Week in Review](#) - Current edition

:: [Informed Consent: A Monthly Review – October 2023](#)

:: [Genomic Medicine – Governance, Ethics, Policy, Practice: A Monthly Digest](#) – Oct 2023

:: [Public Consultations Watch :: Global Calls for Input/Public Comment – 24 Oct 2023 – Issue 09](#)

**GHIT Fund** [to 18 Nov 2023]

<https://www.ghitfund.org/newsroom/press>

*Press Releases*

November 15, 2023

**[GHIT Fund Welcomes EIKEN CHEMICAL as New Sponsor](#)**

**Global Fund** [to 18 Nov 2023] No new digest content identified.

<https://www.theglobalfund.org/en/news/>

*News & Stories*

17 November 2023

**[Global Fund Board Hails Recovery in Fight Against HIV, TB and Malaria After COVID-19 Setbacks, Commits to Strengthen Investments in Climate-Resilient Health Systems](#)**

The Board of the Global Fund to Fight AIDS, Tuberculosis and Malaria held its 50th meeting this week in Geneva, Switzerland. Two months after the release of the Global Fund's Results Report, Board members praised the unprecedented progress achieved i...

14 November 2023

**[The Global Fund Welcomes the Anne and Chris Flowers Foundation's Contribution for Cross-border Malaria Elimination in Southern Africa](#)**

The Global Fund to Fight AIDS, Tuberculosis and Malaria (the Global Fund) welcomes a contribution by the Anne and Chris Flowers Foundation of US\$1 million to support the Global Fund's MOSASWA regional grant, a trilateral agreement between the governm...

**Global Research Collaboration for Infectious Disease Preparedness [GloPID-R]** [to 18 Nov 2023]

<https://www.glopid-r.org/news/>

*News*

*No new digest content identified.*

**Hilleman Laboratories** [to 18 Nov 2023]

<http://www.hilleman-labs.org/>

*News & Insights*

No new digest content identified.

**HHMI - Howard Hughes Medical Institute** [to 18 Nov 2023]

<https://www.hhmi.org/news>

*Press Room*

**[HHMI Awards Six Driving Change Grants to Institutions Committed to Equity, Inclusion](#)**

November 16, 2023

The second round of \$2.5 million grants were awarded to research universities working to build inclusive learning environments for students in science, technology, engineering, and mathematics (STEM).

**Human Vaccines Project** [to 18 Nov 2023]

<http://www.humanvaccinesproject.org/>

*News*

*No new digest content identified.*

**IAVI** [to 18 Nov 2023]

<https://www.iavi.org/>

*Latest News, Features*

*No new digest content identified.*

**INSERM** [to 18 Nov 2023]

<https://www.inserm.fr/en/home/>

*Press Releases*

*No new digest content identified.*

## **International Coalition of Medicines Regulatory Authorities [ICMRA]**

<http://www.icmra.info/drupal/en/news>

*Selected Statements, Press Releases, Research*

17 November 2023

### **[World AMR Awareness Week 2023: Preventing antimicrobial resistance together](#)**

## **ICH - International Council for Harmonisation of Technical Requirements for Pharmaceuticals for Human Use** [to 18 Nov 2023]

<https://www.ich.org/page/press-releases>

*News/Pubs/Press Releases [Selective]*

*No new digest content identified.*

## **ICRC** [to 18 Nov 2023]

<https://www.icrc.org/en/whats-new>

*What's New [Selected]*

### **[Israel and the Occupied Territories: The ICRC urges protection for Gaza civilians evacuating and staying behind](#)**

Hostilities taking place in heavily populated urban areas, including around hospitals, endanger the lives of the most vulnerable people, like medical staff, patients, the wounded, premature babies, people with disabilities, and the elderly."An unbearable

12-11-2023 | News release

## **IFFIm**

<http://www.iffim.org/>

*Press Releases/Announcements*

### **[Severe pneumonia in retreat since PCV jab, say Nepal health workers](#)**

10 Nov 2023

After the pneumococcal conjugate vaccine was introduced in 2015, studies observed a major change in disease rates. Now health workers countrywide say the impact is evident.

## **IFRC** [to 18 Nov 2023]

<http://media.ifrc.org/ifrc/news/press-releases/>

*Press Releases [Selected]*

*Press release 17/11/2023*

### **[IFRC intensifies response to escalating cholera outbreak in Zimbabwe: Emergency appeal](#)**

## **Institut Pasteur** [to 18 Nov 2023]

<https://www.pasteur.fr/en/press-area>

*Press Documents*

*Press Info 15.11.2023*

### **[The Institut Pasteur announces the launch of the Pasteur Foundation – UK](#)**

London, November 15, 2023 - The Institut Pasteur announces the launch of the Pasteur Foundation – UK, a private non-profit foundation aiming to raise awareness and funds for scientific cooperations between the Institut Pasteur in Paris and scientific institutions in the UK.

Press release 14.11.2023

### **Significant "post-COVID" resurgence in invasive meningococcal disease**

A team of scientists from the Institut Pasteur has used the database of the National Reference Center for Meningococci...

### **ISC / International Science Council** [to 18 Nov 2023]

<https://council.science/current/>

*ISC is a non-governmental organization with a unique global membership that brings together 40 international scientific Unions and Associations and over 140 national and regional scientific organizations including Academies and Research Councils.*

*Blogs News*

### **Converging and interdependent crises are amplifying the impacts of one another with often devastating consequences**

Statement by Vivi Stavrou, Senior Science Officer and Executive Secretary of the International Science Council's Committee for Freedom and Responsibility in Science, at the UNESCO 42nd General Conference.

16.11.2023

### **International Union of Immunological Societies (IUIS)**

<https://iuis.org/>

*News/Events [Selected]*

### **18th International Congress of Immunology**

27 November - 2 December 2023 | Cape Town, South Africa

### **IVAC** [to 18 Nov 2023]

<https://www.jhsph.edu/research/centers-and-institutes/ivac/index.html>

*Updates; Events*

*No new digest content identified.*

### **IVI** [to 18 Nov 2023]

<http://www.ivi.int/>

*IVI News & Announcements*

### **IVI signs MOU with University of Cambridge, University of Hong Kong, and the Hong Kong Jockey Club to establish the Hong Kong Jockey Club Global Health Institute**

... to promote vaccine research and global health initiatives, including the establishment of the Hong Kong Jockey Club Global Health Institute (HKJCGHI)...

### **IVI's Global Council elects two members to the Board of Trustees**

At the inaugural Global Council meeting on October 19, 2023, IVI's state party representatives unanimously voted to nominate two members to the Board of Trustees (BOT), the highest governing body of IVI. These two seats are reserved for country delegates from among IVI's State Parties who do not currently provide core funding, a decision taken last year by the Board to further incorporate the perspectives of IVI's members in the governance of the organization.

The IVI BOT confirmed these two nominees and welcomes Dr. Ehsanul Kabir, representing Bangladesh, and congratulates Prof. Leon Mutesa, representing Rwanda...

### **Johns Hopkins Center for Health Security** [to 18 Nov 2023]

<https://www.centerforhealthsecurity.org/news/center-news/>

*Center News [Selected]*

November 14, 2023

**[More than 100 stakeholder groups call on US Congress leadership to reauthorize PAHPA](#)**

More than 100 stakeholders sent a letter to congressional leadership urging them to reauthorize the Pandemic and All-Hazards Preparedness Act (PAHPA) before the end of the calendar year and with the same bipartisan support it has had since its original authorization 17 years ago.

**MSF/Médecins Sans Frontières** [to 18 Nov 2023]

<http://www.msf.org/>

*Latest [Selected Announcements]*

*Myanmar*

**[Medical facilities, patients and healthcare workers must be protected as conflict escalates across Myanmar](#)**

Press Release 18 Nov 2023

*Palestine*

**[Gaza: Trapped by days of unrelenting fighting, thousands of civilians are at risk of dying, including over a hundre...](#)**

Press Release 17 Nov 2023

*Panama*

**[Incidents of sexual violence spike for those crossing Panama's Darién Gap](#)**

Press Release 17 Nov 2023

*Haiti*

**[Cité Soleil clashes severely affect people's access to medical care](#)**

Press Release 17 Nov 2023

*India*

**[MSF to close sexual violence treatment centre in Delhi](#)**

Project Update 16 Nov 2023

*South Sudan*

**[Unshattered hope in the face of adversity in South Sudan](#)**

Project Update 15 Nov 2023

*Tuberculosis*

**[Landmark clinical trial redefines multidrug-resistant tuberculosis treatment options](#)**

Press Release 15 Nov 2023

*Conflict in Sudan*

**[Surgical supply ban in Khartoum must be immediately reversed](#)**

Press Release 14 Nov 2023

**National Academy of Medicine** - USA [to 18 Nov 2023]

<https://nam.edu/programs/>

*News [Selected]*

*No new digest content identified.*

**National Academy of Sciences** - USA [to 18 Nov 2023]

<https://www.nationalacademies.org/newsroom?>

*News*

*No new digest content identified.*

**National Vaccine Program Office** - U.S. HHS [to 18 Nov 2023]

<https://www.hhs.gov/vaccines/about/index.html>

*Upcoming Meetings/Latest Updates*

*No new digest content identified.*

**NIH** [to 18 Nov 2023]

<http://www.nih.gov/>

*News Releases*

*No new digest content identified.*

**PATH** [to 18 Nov 2023]

<https://www.path.org/media-center/>

*Newsroom*

**[USAID, CHRI, and PATH launch a new program on climate and health](#)**

Published: November 2023

Press Release

New Delhi, November 17: The United States Agency for International Development (USAID), the Centre for Health Research and Innovation (CHRI), and PATH announced the launch of the Sustainable Action for Climate Health Alliance for concerted action on climate and health in Indian cities. This initiative, also known as SACH, will bring together policymakers, urban bodies, private sector, health care chains, development organizations, donors, philanthropies, community-based organizations, and innovators to promote cross-sectoral collaboration and improve climate and health outcomes...

**[IOC, WHO, and PATH join forces to strengthen the role of community sport in promoting healthy lives](#)**

A new collaboration between the International Olympic Committee (IOC) and PATH will increase access to health-enhancing community sport activities for over one million people across five countries by 2025.

Published: November 2023

Press Release

**Rockefeller Foundation** [to 18 Nov 2023]

<https://www.rockefellerfoundation.org/>

*Selected Reports/Press Releases*

*No new digest content identified.*

**Sabin Vaccine Institute** [to 18 Nov 2023]

<https://www.sabin.org/press/>

*Latest News & Press Releases*

*No new digest content identified.*

**UNAIDS** [to 18 Nov 2023]

<http://www.unaids.org/en>

*Selected Press Releases/Reports/Statements*

*No new digest content identified.*

**UNICEF** [to 18 Nov 2023]

<https://www.unicef.org/media/press-releases>

*Latest press releases, news notes and statements*

*Statement 16 November 2023*

**[Statement by Principals of the Inter-Agency Standing Committee, Humanitarian chiefs will not take part in unilateral proposals to create "safe zones" in Gaza](https://www.unicef.org/press-releases/statement-principals-inter-agency-standing-committee-humanitarian-chiefs-will-not)**

<https://www.unicef.org/press-releases/statement-principals-inter-agency-standing-committee-humanitarian-chiefs-will-not>

NEW YORK/GENEVA/ROME, 16 November 2023 – As humanitarian leaders, our position is clear: We will not participate in the establishment of any "safe zone" in Gaza that is set up without the agreement of all the parties, and unless fundamental conditions are in place to ensure safety and other essential needs are met and a mechanism is in place to...

*Statement 16 November 2023*

**[Joint statement from the Action Review Panel \(ARP\) on Child Wasting ahead of the Global Food Security Summit in London](https://www.unicef.org/press-releases/joint-statement-action-review-panel-arp-child-wasting-ahead-global-food-security)**

<https://www.unicef.org/press-releases/joint-statement-action-review-panel-arp-child-wasting-ahead-global-food-security>

LONDON/NEW YORK, 16 November 2023 - "Today, rising global hunger and malnutrition pose one of the greatest threats to children's futures. The youngest, poorest and most marginalised children are victims of a perfect storm of increasing conflict, poverty and climate shocks, which risks reversing the remarkable progress made on child survival and...

*Press release 14 November 2023*

**[Statement by UNICEF Executive Director Catherine Russell on her visit to Gaza](https://www.unicef.org/press-releases/statement-unicef-executive-director-catherine-russell-her-visit-gaza)**

<https://www.unicef.org/press-releases/statement-unicef-executive-director-catherine-russell-her-visit-gaza>

GAZA, 15 November 2023 – "Today I visited the Gaza Strip to meet with children, their families and UNICEF staff. What I saw and heard was devastating. They have endured repeated bombardment, loss and displacement. Inside the Strip, there is nowhere safe for Gaza's one million children to turn. "The parties to the conflict are committing grave...

*Press release 13 November 2023*

**[1 in 3 children exposed to severe water scarcity – UNICEF](https://www.unicef.org/press-releases/1-3-children-exposed-severe-water-scarcity-unicef)**

<https://www.unicef.org/press-releases/1-3-children-exposed-severe-water-scarcity-unicef>

NEW YORK, 13 November 2023 – 1 in 3 children – or 739 million worldwide – already live in areas exposed to high or very high water scarcity, with climate change threatening to make this worse, according to a new UNICEF report. Further, the double burden of dwindling water availability and inadequate drinking water and sanitation services is...

**Unitaid** [to 18 Nov 2023]

<https://unitaid.org/>

*Featured News*

17 November 2023

[\*\*Cervical Cancer Day of Elimination: Improving preventive services in low- and middle-income countries\*\*](#)

16 November 2023

[\*\*New preventive treatment for children cuts the risk of drug-resistant tuberculosis by more than half, in first-ever study of its kind\*\*](#)

15 November 2023

[\*\*Landmark Clinical Trial Redefines Multidrug-Resistant Tuberculosis Treatment Options\*\*](#)

**Vaccine Equity Cooperative [nee Initiative]** [to 18 Nov 2023]

<https://vaccineequitycooperative.org/news/>

*News*

*No new digest content identified.*

**Vaccination Acceptance & Demand Initiative (Sabin)** [to 18 Nov 2023]

<https://www.vaccineacceptance.org/>

*Announcements, Blog*

*Blog*

[\*\*VARN2023 Posters\*\*](#)

November 2023

Explore the posters presented at the VARN2023 Conference.

**Vaccine Confidence Project** [to 18 Nov 2023]

<http://www.vaccineconfidence.org/>

*News, Research and Reports*

*No new digest content identified.*

**Vaccine Education Center – Children’s Hospital of Philadelphia** [to 18 Nov 2023]

<http://www.chop.edu/centers-programs/vaccine-education-center>

*News*

*No new digest content identified.*

**Wellcome Trust** [to 18 Nov 2023]

<https://wellcome.ac.uk/news>

*News, Opinion, Reports*

*Explainer*

[\*\*Why is it so hard to develop new antibiotics?\*\*](#)

17 November 2023

**The Wistar Institute** [to 18 Nov 2023]

<https://www.wistar.org/news/press-releases>

*Press Releases*

*No new digest content identified.*



**World Bank** [to 015 Oct 2022]

<http://www.worldbank.org/en/news/all>

*All News [Selected]*

### **Antimicrobial Resistance (AMR)**

*Antimicrobials are drugs – such as antibiotics – that kill or control disease-causing microbes.*

Antimicrobial resistance (AMR) occurs when microbes mutate or adapt in ways that enable them to withstand...

Date: November 14, 2023 Type: Brief

**WFPHA: World Federation of Public Health Associations** [to 18 Nov 2023]

<https://www.wfpha.org/>

*Latest News - Blog*

### **World Federation of Public Health Associations Endorses SESPAS Statement**

Nov 16, 2023

World Federation of Public Health Associations Endorses SESPAS Statement The Spanish Society for Public Health and Health Administration (SESPAS) has strongly denounced the dire humanitarian situation in the Gaza Strip, emphasizing the devastating impact on public health...

**World Medical Association [WMA]** [to 18 Nov 2023]

<https://www.wma.net/news-press/press-releases/>

*Press Releases*

*No new digest content identified.*

**World Organisation for Animal Health** [to 18 Nov 2023]

<https://www.oie.int/en/>

*Press Releases, Statements*

*News*

### **Preserving antimicrobials as lifesavers for humans, animals, plants and ecosystems**

*Quadripartite holds inaugural Plenary Assembly of the AMR Multi-Stakeholder Partnership Platform*  
Published on 15 November 2023

Rome – The first Plenary Assembly of the Antimicrobial Resistance Multi-Stakeholder Partnership Platform opened today at the Rome headquarters of the Food and Agriculture Organization of the United Nations (FAO).

The two-day meeting, which is being held ahead of 2023 World AMR Awareness Week, brings together more than 150 stakeholders from around the globe, encompassing governments, civil society, research, academia, the private sector, financial institutions, intergovernmental organizations and specialized UN agencies. Its overarching aim is to collectively address ways of preserving antimicrobials as lifesaving medicines for humans, animals, plants and ecosystems using the One Health approach...

.....

**ARM [Alliance for Regenerative Medicine]** [to 18 Nov 2023]

<https://alliancerm.org/press-releases/>

*Selected Press Releases*

*No new digest content identified.*

**BIO** [to 18 Nov 2023]

<https://www.bio.org/press-releases>

*Press Releases*

*No new digest content identified.*

**DCVMN – Developing Country Vaccine Manufacturers Network** [to 18 Nov 2023]

<http://www.dcvmn.org/>

*News; Upcoming events*

*No new digest content identified.*

**ICBA – International Council of Biotechnology Associations** [to 18 Nov 2023]

<https://internationalbiotech.org/news/>

*News*

*No new digest content identified.*

**IFPMA** [to 18 Nov 2023]

<https://ifpma.org/>

*Selected Press Releases/Statements*

*External study 16 Nov 2023*

### **[The socio-economic value of adult immunization \(OHE\)](#)**

This study by the Office of Health Economics (OHE) synthesizes existing evidence for the broad, socio-economic value of adult immunization programs, focusing on influenza, pneumococcal, herpes zoster (HZ), and respiratory syncytial virus (RSV) programs in ten countries (Australia, Brazil, France, Germany, Italy, Japan, Poland, South Africa, Thailand, United States).

In a forthcoming publication, OHE will present the results of a cost-benefit analysis to quantify the societal return on investment for vaccination programs in these countries.

This study was commissioned by IFPMA.

PDF: [https://www.ifpma.org/wp-](https://www.ifpma.org/wp-content/uploads/2023/11/231116_Socio_Economic_Value_Adult_Immunization_OHE-1.pdf)

[content/uploads/2023/11/231116\\_Socio\\_Economic\\_Value\\_Adult\\_Immunization\\_OHE-1.pdf](https://www.ifpma.org/wp-content/uploads/2023/11/231116_Socio_Economic_Value_Adult_Immunization_OHE-1.pdf)

**International Alliance of Patients' Organizations – IAPO** [to 18 Nov 2023]

<https://www.iapo.org.uk/news>

*Press and media [Selected]*

*No new digest announcements identified*

**International Generic and Biosimilar Medicines Association [IGBA]**

<https://www.igbamedicines.org/>

*News*

### **[GBA's Annual Global Biosimilars Week Focuses on Oncology Care \(November 2023\)](#)**

Geneva, November 13, 2023 – In the week ahead, IGBA will renew its commitment to raise awareness of the powerful and lifechanging impact of biosimilar medicines which contribute to delivering better health outcomes and biologics access equity for more patients. The fourth Global Biosimilars Week (GBW) will run from 13th to 17th November, 2023 on social media, supported by a rich resource dedicated website [globalbiosimilarsweek.org](http://globalbiosimilarsweek.org).

**PhRMA** [to 18 Nov 2023]

<http://www.phrma.org/>

*Press Releases*

*No new digest announcements identified*



## ***Vaccines/Therapeutics/Medicines – Selected Developer/Manufacturer Announcements***

### **AstraZeneca**

*Press Releases* - No new digest announcements identified.

### **Bharat Biotech**

*Press Releases* - No new digest announcements identified.

### **BioCubaFarma – Cuba**

*Últimas Noticias* - Website not responding at inquiry

### **Biological E**

*News* - No new digest announcements identified

### **BioNTech**

*Press Releases* - No new digest announcements identified.

### **Boehringer**

*Press Releases* - No new digest announcements identified.

### **CanSinoBIO**

*News* - Website not responding at inquiry

### **CIGB**

*Latest News* - No new digest announcements identified.

### **Cinnagen**

*Recent News* - No new digest announcements identified.

### **Clover Biopharmaceuticals - China**

*News* - No new digest announcements identified.

### **Curevac [Bayer Ag – Germany]**

*News*

*Press Release* November 14, 2023

#### **[CureVac Announces Financial Results for the Third Quarter and First Nine Months of 2023 and Provides Business Update](#)**

- Enrollment completed for Phase 2 COVID-19 study with mono- and bivalent vaccine candidates; study on track for data read-out in early 2024
- First participant dosed in seasonal flu Phase 2 study with potentially differentiated multivalent candidate; €15 million milestone payment by GSK triggered
- Phase 1 study in glioblastoma well on track with opening of third dose level for CVGBM, CureVac's multipeptide cancer vaccine candidate
- The RNA Printer® achieved first milestone, obtaining manufacturing license for GMP-grade mRNA manufacturing in cancer vaccine development

- Chief Business and Commercial Officer to leave CureVac at the end of his term, effective November 30, 2023

### **Gamaleya National Center/Sputnik**

Latest News and Events - No new digest announcements identified  
<https://sputnikvaccine.com/> - No new digest announcements identified

### **GSK**

Press releases for media - No new digest announcements identified.

### **IMBCAMS, China**

Home - Website not responding at inquiry.

### **Janssen/JNJ**

Press Releases - No new digest announcements identified.

### **Merck**

News releases - No new digest announcements identified

### **Moderna**

Press Releases - No new digest announcements identified

### **Nanogen**

News - No new digest announcements identified

### **Novartis**

News - No new digest announcements identified.

### **Novavax**

Press Releases

Nov 17, 2023 *Corporate and finance*

### **[Novavax Makes Changes to Executive Leadership Team to Enhance Focus on Delivery of Strategic Priorities](#)**

- New organizational structure for executive leadership team designed to facilitate a leaner and more focused approach to annual execution of business plans
- John Trizzino appointed to new Chief Operating Officer role
- Mark Casey to join as Chief Legal Officer and Corporate Secretary

### **Pfizer**

Recent Press Releases - No new digest announcements identified.

### **R-Pharm**

<https://rpharm-us.com/index.php>

[No news or media page identified]

### **Sanofi Pasteur**

Press Releases - No new digest announcements identified.

### **Serum Institute of India**

NEWS & ANNOUNCEMENTS - No new digest announcements identified

### **Sinopharm/WIBPBIBP**

*News - No new digest announcements identified [English translation function not operating]*

## **Sinovac**

*Press Releases - No new digest announcements identified.*

## **SK Biosciences**

*Press Releases - No new digest announcements identified.*

## **Takeda**

*Newsroom - No new digest announcements identified.*

## **Valneva**

*Press Releases*

November 13, 2023

[\*\*Valneva Reports Positive Pivotal Phase 3 Immunogenicity Data in Adolescents for its Single-Shot Chikungunya Vaccine Candidate\*\*](#)

## **Vector State Research Centre of Virology and Biotechnology**

*Home - Website not responding [404 error]*

## **WestVac Biopharma**

*Media - No new digest announcements identified*

## **Zhifei Longcom, China**

[Anhui Zhifei Longcom Biologic Pharmacy Co., Ltd.]

*[No website identified]*

.....  
.....

### ***Contents [click to move among sections]***

*:: [Milestones, Perspectives](#)*

*:: [WHO](#)*

*:: [Organization Announcements](#)*

*:: [Journal Watch](#)*

*:: [Pre-Print Servers](#)*

.....  
.....

## ***Journal Watch***

*Vaccines and Global Health: The Week in Review* continues its weekly scanning of key peer-reviewed journals to identify and cite articles, commentary and editorials, books reviews and other content supporting our focus on vaccine ethics and policy. Journal Watch is not intended to be exhaustive, but indicative of themes and issues the Center is actively tracking. We selectively provide full text of some editorial and comment articles that are specifically relevant to our work. Successful access to some of the links provided may require subscription or other access arrangement unique to the publisher.

If you would like to suggest other journal titles to include in this service, please contact David Curry at: [david.r.curry@centerforvaccineethicsandpolicy.org](mailto:david.r.curry@centerforvaccineethicsandpolicy.org)

## **AJOB Empirical Bioethics**

Volume 14, 2023 Issue 4

<https://www.tandfonline.com/toc/uabr21/current>

[Reviewed earlier]

### **AMA Journal of Ethics**

Volume 25, Number 11: E791-854 Nov 2023

<https://journalofethics.ama-assn.org/issue/health-and-loneliness>

#### ***Health and Loneliness***

Human experiences of loneliness come from perceived deficits in social interaction. Loneliness first became a health concern due to its associations with increased mortality and functional decline, especially among elders. However, its increasing prevalence across age groups in the US calls for our health care system to pay clinical and ethical attention to loneliness as a common experience in American life. This theme issue considers loneliness as a key source of health vulnerabilities that remains underappreciated and provides insights as to how our health care system can more fully respond to the needs of patients with limited social networks.

### **American Journal of Human Genetics**

Nov 02, 2023 Volume 110 Issue 11 p1827-1986

<https://www.cell.com/ajhg/current>

[Reviewed earlier]

### **American Journal of Infection Control**

November 2023 Volume 51 Issue 11 p1201-1294

<http://www.ajicjournal.org/current>

[Reviewed earlier]

### **American Journal of Preventive Medicine**

November 2023 Volume 65 Issue 5 p763-952

<https://www.ajpmonline.org/current>

[Reviewed earlier]

### **American Journal of Public Health**

November 2023 113(11)

<http://ajph.aphapublications.org/toc/ajph/current>

[Reviewed earlier]

### **American Journal of Tropical Medicine and Hygiene**

Volume 109 (2023): Issue 4 (Oct 2023)

<https://www.ajtmh.org/view/journals/tpmd/109/4/tpmd.109.issue-4.xml>

[Reviewed earlier]

### **Annals of Internal Medicine**

October 2023 Volume 176, Issue 10

<https://www.acpjournals.org/toc/aim/current>

[Reviewed earlier]

## **Artificial Intelligence – An International Journal**

Volume 324 November 2023

<https://www.sciencedirect.com/journal/artificial-intelligence/vol/324/suppl/C>

[Reviewed earlier]

## **BMC Cost Effectiveness and Resource Allocation**

<http://resource-allocation.biomedcentral.com/>

(Accessed 18 Nov 2023)

[No new digest content identified]

## **BMC Health Services Research**

<http://www.biomedcentral.com/bmchealthservres/content>

(Accessed 18 Nov 2023)

### **[Socioecological systems analysis of potential factors for cholera outbreaks and assessment of health system's readiness to detect and respond in Ilemela and Nkasi districts, Tanzania](#)**

*Cholera outbreaks are a recurrent issue in Tanzania, with Ilemela and Nkasi districts being particularly affected. The objective of this study was to conduct a socio-ecological system (SES) analysis of cholera ...*

Authors: Baraka L. Ngingo, Zaina S. Mchome, Veneranda M. Bwana, Augustino Chengula, Gaspari Mwanyika, Irene Mremi, Calvin Sindato and Leonard E.G. Mboera

Citation: BMC Health Services Research 2023 23:1261

Content type: Research Published on: 15 November 2023

## **BMC Infectious Diseases**

<http://www.biomedcentral.com/bmcinfectdis/content>

(Accessed 18 Nov 2023)

[No new digest content identified]

## **BMC Medical Ethics**

<http://www.biomedcentral.com/bmcmedethics/content>

(Accessed 18 Nov 2023)

[No new digest content identified]

## **BMC Medicine**

<http://www.biomedcentral.com/bmcmed/content>

(Accessed 18 Nov 2023)

### **[A mathematical model of Marburg virus disease outbreaks and the potential role of vaccination in control](#)**

*Marburg virus disease is an acute haemorrhagic fever caused by Marburg virus. Marburg virus is zoonotic, maintained in nature in Egyptian fruit bats, with occasional spillover infections into humans and nonhum...*

Authors: George Y. Qian, W. John Edmunds, Daniel G. Bausch and Thibaut Jombart

Citation: BMC Medicine 2023 21:439

Content type: Research article Published on: 14 November 2023

**[A quantitative evaluation of the impact of vaccine roll-out rate and coverage on reducing deaths: insights from the first 2 years of COVID-19 epidemic in Iran](#)**

*Vaccination has played a pivotal role in reducing the burden of COVID-19. Despite numerous studies highlighting its benefits in reducing the risk of severe disease and death, we still lack a quantitative under...*

Authors: Mahan Ghafari, Sepanta Hosseinpour, Mohammad Saeid Rezaee-Zavareh, Stefan Dascalu, Somayeh Rostamian, Kiarash Aramesh, Kaveh Madani and Shahram Kordasti

Citation: BMC Medicine 2023 21:429

Content type: Research article Published on: 13 November 2023

**BMC Pregnancy and Childbirth**

<http://www.biomedcentral.com/bmcpregnancychildbirth/content>

(Accessed 18 Nov 2023)

[No new digest content identified]

**BMC Public Health**

<http://bmcpublichealth.biomedcentral.com/articles>

(Accessed 18 Nov 2023)

**[RTS,S/AS01 malaria vaccine pilot implementation in western Kenya: a qualitative longitudinal study to understand immunisation barriers and optimise uptake](#)**

*Malaria is a significant public health threat in sub-Saharan Africa, particularly among children. The RTS,S/AS01 malaria vaccine reduces the risk and severity of malaria in children. RTS,S/AS01 was piloted in ...*

Authors: Jenna Hoyt, George Okello, Teresa Bange, Simon Kariuki, Mohamed F. Jalloh, Jayne Webster and Jenny Hill

Citation: BMC Public Health 2023 23:2283

Content type: Research Published on: 18 November 2023

**[Assessing the impact of COVID-19 passes and mandates on disease transmission, vaccination intention, and uptake: a scoping review](#)**

*Policymakers have struggled to maintain SARS-CoV-2 transmission at levels that are manageable to contain the COVID-19 disease burden while enabling a maximum of societal and economic activities. One of the too...*

Authors: Yessika Adelwin Natalia, Margaux Delporte, Dries De Witte, Philippe Beutels, Mathias Dewatripont and Geert Molenberghs

Citation: BMC Public Health 2023 23:2279

Content type: Research Published on: 17 November 2023

**[Cost-effectiveness analysis of typhoid vaccination in Lao PDR](#)**

*Typhoid vaccination has been shown to be an effective intervention to prevent enteric fever and is under consideration for inclusion in the national immunization program in Lao PDR.*

Authors: Mick Soukavong, Nantasit Luangsanatip, Phetsavanh Chanthavilay, Yot Teerawattananon, Saudamini Vishwanath Dabak, Wirichada Pan-ngum, Tamalee Roberts, Elizabeth A Ashley and Mayfong Mayxay

Citation: BMC Public Health 2023 23:2270

Content type: Research Published on: 17 November 2023

**BMC Research Notes**



<http://www.biomedcentral.com/bmcresnotes/content>

(Accessed 18 Nov 2023)

[No new digest content identified]

### **BMJ Evidence-Based Medicine**

October 2023 - Volume 28 - 5

<https://ebm.bmj.com/content/28/5>

[Reviewed earlier]

### **BMJ Global Health**

October 2023 - Volume 8 - 10

<https://gh.bmj.com/content/8/10>

[Reviewed earlier]

### **Bulletin of the Atomic Scientists**

September 2023

<https://thebulletin.org/magazine/2023-09/>

*Contents*

[Reviewed earlier]

### **Bulletin of the World Health Organization**

Volume 101(10); 2023 Oct 1

<https://www.ncbi.nlm.nih.gov/pmc/issues/446112/>

[Reviewed earlier]

### **Cell**

Nov 09, 2023 Volume 186 Issue 23 p4975-5200

<https://www.cell.com/cell/current>

[New issue; No digest content identified]

### **Child Care, Health and Development**

Volume 49, Issue 6 Pages: 941-1111 November 2023

<https://onlinelibrary.wiley.com/toc/13652214/current>

[Reviewed earlier]

### **Clinical Pharmacology & Therapeutics**

Volume 114, Issue 5 Pages: 933-1141 November 2023

<https://ascpt.onlinelibrary.wiley.com/toc/15326535/current>

[Reviewed earlier]

### **Clinical Therapeutics**

October 2023 Volume 45 Issue 10 p925-1014

<http://www.clinicaltherapeutics.com/current>

[Reviewed earlier]

### **Clinical Trials**

Volume 20 Issue 6, December 2023

<https://journals.sagepub.com/toc/ctja/20/6>

[New issue; No digest content identified]

### **Conflict and Health**

<http://www.conflictandhealth.com/>

[Accessed 18 Nov 2023]

[No new digest content identified]

### **Contemporary Clinical Trials**

Volume 133 October 2023

<https://www.sciencedirect.com/journal/contemporary-clinical-trials/vol/133/suppl/C>

[Reviewed earlier]

### **The CRISPR Journal**

Volume 6, Issue 5 / October 2023

<https://www.liebertpub.com/toc/crispr/6/5>

[Reviewed earlier]

### **Current Genetic Medicine Reports**

Volume 10, issue 3, September 2022

<https://link.springer.com/journal/40142/volumes-and-issues/10-3>

[Reviewed earlier]

### **Current Medical Research and Opinion**

Volume 39, Issue 10 2023

<https://www.tandfonline.com/toc/icmo20/current>

[Reviewed earlier]

### **Current Opinion in Infectious Diseases**

December 2023 - Volume 36 - Issue 6

<https://journals.lww.com/co-infectiousdiseases/pages/currenttoc.aspx>

[New issue; No digest content identified]

### **Current Protocols in Human Genetics**

<https://currentprotocols.onlinelibrary.wiley.com/journal/19348258>

[Accessed 18 Nov 2023]

[No new digest content identified]

### **Developing World Bioethics**

Volume 23, Issue 3 Pages: 197-292 September 2023

<https://onlinelibrary.wiley.com/toc/14718847/current>

[Reviewed earlier]

### **Development in Practice**

Volume 33, Issue 8, 2023

<http://www.tandfonline.com/toc/cdip20/current>

[Reviewed earlier]

### **Development Policy Review**

Volume 41, Issue 6 November 2023

<https://onlinelibrary.wiley.com/toc/14677679/current>

[Reviewed earlier]

### **Disaster Medicine and Public Health Preparedness**

Volume 16 - Issue 6 - December 2022

<https://www.cambridge.org/core/journals/disaster-medicine-and-public-health-preparedness/latest-issue>

[Reviewed earlier]

### **Disasters**

Volume 47, Issue 3 Pages: 543-846 July 2023

<https://onlinelibrary.wiley.com/toc/14677717/2023/47/3>

[Reviewed earlier]

### **EMBO Reports**

Volume 24 Issue 11 6 November 2023

<https://www.embopress.org/toc/14693178/current>

[Reviewed earlier]

### **Emerging Infectious Diseases**

Volume 29, Number 10—October 2023

<http://wwwnc.cdc.gov/eid/>

[Reviewed earlier]

### **Epidemics**

Volume 44 September 2023

<https://www.sciencedirect.com/journal/epidemics/vol/44/suppl/C>

[Reviewed earlier]

### **Epidemiology and Infection**

Volume 151 - 2023

<https://www.cambridge.org/core/journals/epidemiology-and-infection/latest-issue>

[Reviewed earlier]

### **Ethics & Human Research**

Volume 45, Issue 5 Pages: 1-47 September–October 2023

<https://onlinelibrary.wiley.com/toc/25782363/current>

***Adaptive clinical trials :: Deprioritizing ongoing clinical trials***

[Reviewed earlier]

### **Ethics & International Affairs**

Volume 37 - Issue 2 - Summer 2023

<https://www.cambridge.org/core/journals/ethics-and-international-affairs/latest-issue>

[Reviewed earlier]

### **Ethics, Medicine and Public Health**

Volume 30 October 2023

<https://www.sciencedirect.com/journal/ethics-medicine-and-public-health/vol/30/suppl/C>

[Reviewed earlier]

### **The European Journal of Public Health**

Volume 33, Issue 5, October 2023

<https://academic.oup.com/eurpub/issue/33/5>

[Reviewed earlier]

### **Expert Review of Vaccines**

Vol 22 (1) 2023

<https://www.tandfonline.com/toc/ierv20/current>

[Reviewed earlier]

### **Foreign Affairs**

September/October 2023 Volume 102, Number 5

<https://www.foreignaffairs.com/issues/2023/102/5>

[Reviewed earlier]

### **Forum for Development Studies**

Volume 50, 2023 - Issue 3

<http://www.tandfonline.com/toc/sfds20/current>

[Reviewed earlier]

### **Genetics in Medicines**

Volume 25, Issue 11 November 2023

<https://www.sciencedirect.com/journal/genetics-in-medicine/vol/25/issue/11>

[Reviewed earlier]

### **Genome Medicine**

<https://genomemedicine.biomedcentral.com/articles>

[Accessed 18 Nov 2023]  
[New issue; No digest content identified]

### **Global Health Action**

Volume 16, Issue 1 (2023)  
<https://www.tandfonline.com/toc/zgha20/current?nav=toCList>  
[Reviewed earlier]

### **Global Health: Science and Practice (GHSP)**

Vol. 11, No. 5 October 30, 2023  
<http://www.ghspjournal.org/content/current>  
[Reviewed earlier]

### **Global Legal Monitor – Library of Congress/USA**

<https://www.loc.gov/collections/global-legal-monitor/>  
[Accessed 18 Nov 2023]  
[No new digest content identified]

### **Global Public Health**

Volume 18, Issue 1 (2023)  
<http://www.tandfonline.com/toc/rgph20/current>  
[Reviewed earlier]

### **Globalization and Health**

<http://www.globalizationandhealth.com/>  
[Accessed 18 Nov 2023]  
[No new digest content identified]

### **Health and Human Rights**

Volume 25, Issue 1, June 2023,  
<https://www.hhrjournal.org/special-section-global-voices-for-global-equity-expanding-right-to-health-frameworks/>

#### ***Special Section: Global Voices for Global Justice: Expanding Right to Health Frameworks***

...The papers in this special section work together to move toward a global social medicine for the 22nd century. They envision a global social medicine that confronts and moves beyond the traditionally colonial, xenophobic, heteronormative, patriarchal, gender-binary-bound, capitalist, and racist histories of the fields of global health and human rights. They seek to instantiate a global social medicine that centers knowledge and experiences from the Global South and works toward social justice and health equity at scale. In this special section, the authors are particularly interested in understanding, challenging, and expanding our perspectives and enactments of the right to health. Unlike neoliberal perspectives on health that often limit their explanatory capacity to how individuals behave in the world, the papers here move beyond the focus on lifestyles and on the phantasmagoria of a sovereign subject with supposedly free agency. Instead, authors work toward critical consciousness that accounts for structural processes—with their inequities and disruptions, as well as their effects on individuals—and how this consciousness can open new horizons for collective transformation and social emancipation in health...

### **Health Economics, Policy and Law**

Volume 18 - Special Issue 4 - October 2023

<https://www.cambridge.org/core/journals/health-economics-policy-and-law/latest-issue>

***SPECIAL ISSUE: On the roof top of health policy change***

[Reviewed earlier]

### **Health Policy and Planning**

Volume 38, Issue 8, October 2023

<https://academic.oup.com/heapol/issue/38/8>

[Reviewed earlier]

### **Health Research Policy and Systems**

<http://www.health-policy-systems.com/content>

[Accessed 18 Nov 2023]

[No new digest content identified]

### **Human Gene Therapy**

Volume 34, Issue 19-20 / October 2023

<https://www.liebertpub.com/toc/hum/34/19-20>

[Reviewed earlier]

### **Humanitarian Practice Network**

<https://odihpn.org/>

*Featured Publications*

[No new digest content identified]

### **Human Vaccines & Immunotherapeutics** (formerly Human Vaccines)

Volume 19, Issue 3, 2023

<https://www.tandfonline.com/toc/khvi20/19/3?nav=tocList>

[Reviewed earlier]

### **Immunity**

Oct 10, 2023 Volume 56 Issue 10 p2177-2456

<https://www.cell.com/immunity/current>

[Reviewed earlier]

### **Infectious Agents and Cancer**

<http://www.infectagentscancer.com/>

[Accessed 18 Nov 2023]

[No new digest content identified]

### **Infectious Diseases of Poverty**

<http://www.idpjournal.com/content>

[Accessed 18 Nov 2023]

[No new digest content identified]

### **International Health**

Volume 15, Issue 5, September 2023

<https://academic.oup.com/inthealth/issue/15/5>

[Reviewed earlier]

### **International Human Rights Law Review**

Volume 12 (2023): Issue 1 (Jul 2023)

<https://brill.com/view/journals/hrlr/12/1/hrlr.12.issue-1.xml>

*Table of Contents*

[Reviewed earlier]

### **International Journal of Community Medicine and Public Health**

Vol. 10 No. 9 (2023): September 2023

<https://www.ijcmph.com/index.php/ijcmph/issue/view/104>

[Reviewed earlier]

### **International Journal of Epidemiology**

Volume 52, Issue 5, October 2023

<https://academic.oup.com/ije/issue>

[Reviewed earlier]

### **International Journal of Human Rights in Healthcare**

Volume 16 Issue 3 2023

<https://www.emerald.com/insight/publication/issn/2056-4902/vol/16/iss/3>

*Table of contents*

[Reviewed earlier]

### **JAMA**

November 14, 2023, Vol 330, No. 18, Pages 1715-1810

<https://jamanetwork.com/journals/jama/currentissue>

*Research Letter*

#### **[Influenza Antiviral Shortages Reported by State and Territorial Public Health Officials, 2022-2023](#)**

Noah Kojima, MD; Lisa Peterson, MPH, MPA; Regina Hawkins, MPH; et al.

JAMA. 2023;330(18):1793-1795. doi:10.1001/jama.2023.17244

This study provides survey results from state and territorial public health preparedness directors regarding antiviral shortages during the 2022-2023 respiratory viral season.

*US Preventive Services Task Force*

#### **[PEPFAR Reauthorization by Congress Urgent for Global Health](#)**

Monica Gandhi, MD, MPH; Eric Goosby, MD

JAMA. 2023;330(18):1727-1728. doi:10.1001/jama.2023.19322

This Viewpoint discusses the importance of the US Congress reauthorizing funding for the President's Emergency Plan for AIDS Relief, a program developed in 2003 that has played a critical role in fighting HIV/AIDS worldwide as well as other emerging infections and noncommunicable diseases.

### **JAMA Health Forum**

November 2023, Vol 4, No. 11

<https://jamanetwork.com/journals/jama-health-forum/issue>

*JAMA Forum*

#### **Data to Improve Global Health Equity—Key Challenges**

Sandro Galea, MD, DrPH; Salma M. Abdalla, MB BS, DrPH

open access

JAMA Health Forum. 2023;4(11):e234433. doi:10.1001/jamahealthforum.2023.4433

This JAMA Forum discusses how to use data to help achieve global health equity, the challenges in using data to narrow health gaps, and ways to work toward a world with fewer health gaps.

#### **A Historic Moment in Global Health—"Futureproofing" the World Against Pandemics**

Lawrence O. Gostin, JD

open access

JAMA Health Forum. 2023;4(11):e234804. doi:10.1001/jamahealthforum.2023.4804

This JAMA Forum discusses the International Health Regulations of the World Health Organization, political declarations of the United Nations, and a pandemic agreement proposed by the World Health Assembly and suggests 5 reforms that could improve pandemic prevention, preparedness, and response.

### **JAMA Pediatrics**

November 2023, Vol 177, No. 11, Pages 1115-1244

<https://jamanetwork.com/journals/jamapediatrics/currentissue>

*Viewpoint*

#### **Cost-Related Barriers and Ensuring Equitable Access to Vaccines in the US**

Utibe R. Essien, MD, MPH; Stacie B. Dusetzina, PhD

free access

JAMA Pediatr. 2023;177(11):1117-1118. doi:10.1001/jamapediatrics.2023.3260

This Viewpoint discusses policies toward increasing access to effective COVID-19 vaccines, advancing vaccine equity, strengthening reimbursement policies, and increasing federal incentives for insurers and health systems to improve COVID-19 vaccine uptake.

### **JBI Evidence Synthesis**

November 2023 Volume 73 Issue 5 p797-966

<https://journals.lww.com/jbisrir/Pages/currenttoc.aspx>

[Reviewed earlier]

### **Journal of Adolescent Health**

November 2023 Volume 73 Issue 5 p797-966

<https://www.jahonline.org/current>

[Reviewed earlier]



### **Journal of Artificial Intelligence Research**

Vol. 78 (2023)

<https://www.jair.org/index.php/jair>

*Contents*

[Reviewed earlier]

### **Journal of Community Health**

Volume 48, issue 6, December 2023

<https://link.springer.com/journal/10900/volumes-and-issues/48-6>

[Reviewed earlier]

### **Journal of Current Medical Research and Opinion**

*...a peer-reviewed, international journal for the rapid publication of original research on new and existing drugs and therapies, and post-marketing investigations. Equivalence, safety and efficacy/effectiveness studies are especially encouraged.*

June 18, 2023 Vol 6, No 06 (2023)

<https://www.cmro.in/index.php/jcmro/issue/view/68>

[Reviewed earlier]

### **Journal of Development Economics**

Volume 165 October 2023

<https://www.sciencedirect.com/journal/journal-of-development-economics/vol/165/suppl/C>

[Reviewed earlier]

### **Journal of Empirical Research on Human Research Ethics**

Volume 18 Issue 4, October 2023

<http://journals.sagepub.com/toc/jre/current>

***Ethical Issues in Research in Low and Middle-Income Countries***

[Reviewed earlier]

### **Journal of Epidemiology & Community Health**

September 2023 - Volume 77 - 9

<https://jech.bmj.com/content/77/9>

[Reviewed earlier]

### **Journal of Evidence-Based Medicine**

Volume 16, Issue 3 Pages: 259-413 September 2023

<https://onlinelibrary.wiley.com/toc/17565391/current>

[Reviewed earlier]

### **Journal of Global Ethics**

Volume 19, Issue 2 (2023)

<http://www.tandfonline.com/toc/rjge20/current>

[Reviewed earlier]

**Journal of Health Care for the Poor and Underserved (JHCPU)**

Volume 34, Number 3, August 2023

<https://muse.jhu.edu/issue/50808>

*Table of Contents*

[Reviewed earlier]

**Journal of Immigrant and Minority Health**

Volume 25, issue 6, December 2023

<https://link.springer.com/journal/10903/volumes-and-issues/25-6>

**[COVID-19 Vaccine Acceptance Among Latino/a Immigrants: The Role of Collective Responsibility and Confidence](#)**

Authors (first, second and last of 7)

C. Kirchoff

A. Penn

M. Sanchez

Content type: Original Paper

Published: 04 July 2023

Pages: 1246 – 1253

**[Access to Healthcare Among US Adult Refugees: A Systematic Qualitative Review](#)**

Authors (first, second and last of 8)

Chi H. Ho

Andrea H. Denton

Fern R. Hauck

Content type: Review Paper

Published: 02 April 2023

Pages: 1426 - 1462

**Journal of Immigrant & Refugee Studies**

Volume 21, 2023 \_ Issue 4

<https://www.tandfonline.com/toc/wimm20/current>

[New issue; No digest content identified]

**Journal of Infectious Diseases**

Volume 228, Issue 5, 1 September 2023

<https://academic.oup.com/jid/issue/228/5>

[Reviewed earlier]

**Journal of International Development**

Volume 35, Issue 8 Pages: 2251-2685 November 2023

<https://onlinelibrary.wiley.com/toc/10991328/current>

[New issue; No digest content identified]

**Journal of Medical Ethics**

November 2023 - Volume 49 - 11

<http://jme.bmj.com/content/current>

[Reviewed earlier]

### **Journal of Patient-Centered Research and Reviews**

Volume 10, Issue 3 (2023)

<https://institutionalrepository.aah.org/jpcrr/>

[Reviewed earlier]

### **The Journal of Pediatrics**

Volume 261, October 2023

<https://www.sciencedirect.com/journal/the-journal-of-pediatrics/vol/261/suppl/C>

[Reviewed earlier]

### **Journal of Pharmaceutical Policy and Practice**

<https://joppp.biomedcentral.com/>

[Accessed 18 Nov 2023]

#### **Assessment of vaccine management performance in health facilities of Mwanza Region, Tanzania: a cross-sectional study**

*Effective Vaccine Management (EVM) initiative provides the platform needed to monitor and assess the vaccine supply chain system to identify strengths and weaknesses of the system at all levels and enhance the...*

Authors: Green Sadru, Mulatedzi Makhado, Omary Swalehe, Stany Banzimana, Domina Asingizwe and Shital Mahindra Maru

Citation: Journal of Pharmaceutical Policy and Practice 2023 16:144

Content type: Research Published on: 15 November 2023

#### **Factors that influence the availability of childhood vaccine in healthcare facilities at Tana River County, Kenya**

*Routine vaccine is a cost-effective health intervention against vaccine preventable diseases (VPD). Tremendous gains have been realized since the introduction of vaccines. Despite the gains, access to the life...*

Authors: Billy Said Mkamba, Eugene Rutungwa, Peter Ndirangu Karimi and Joseph Lune Ngenzi

Citation: Journal of Pharmaceutical Policy and Practice 2023 16:142

Content type: Research Published on: 13 November 2023

#### **Examining corruption risks in the procurement and distribution of COVID-19 vaccines in select states in Nigeria**

*Public health emergencies raise significant concerns about corruption and accountability; however, these concerns can manifest in different ways across diverse locations. For instance, more developed countries...*

Authors: Obinna Onwujekwe, Charles Orjiakor, Pamela Ogbozor, Ifunanya Agu, Prince Agwu, Tom Wright, Dina Balabanova and Jillian Kohler

Citation: Journal of Pharmaceutical Policy and Practice 2023 16:141

Content type: Research Published on: 13 November 2023

### **Journal of Public Health Management & Practice**

January/February 2024 - Volume 30 - Issue 1

<https://journals.lww.com/jphmp/pages/currenttoc.aspx>

**Reducing Vaccination Disparities During a National Emergency Response: The US Mpox Vaccine Equity Pilot Program**

Bautista, Gregorio J.; Madera-Garcia, Valerie; Carter, Rosalind J.; More  
Journal of Public Health Management and Practice. 30(1):122-129, January/February 2024.

**From Pandemic to Epidemic: Lessons Learned From COVID-19 Applied to Mpox Outbreak Response, Westchester County, Metropolitan New York**

Keller, Marina; Hellman, Melissa; Hewlett, Dial Jr; More  
Journal of Public Health Management and Practice. 30(1):E1-E4, January/February 2024.

**Journal of Public Health Policy**

Volume 44, issue 3, September 2023

<https://link.springer.com/journal/41271/volumes-and-issues/44-3>

[Reviewed earlier]

**Journal of the Royal Society – Interface**

November 2023 Volume 20 Issue 208

<https://royalsocietypublishing.org/toc/rsif/current>

[Reviewed earlier]

**Journal of Travel Medicine**

Volume 30, Issue 6, August 2023

<https://academic.oup.com/jtm/issue>

[Reviewed earlier]

**Journal of Virology**

Volume 97 Number 9 September 2023

<http://jvi.asm.org/content/current>

[Reviewed earlier]

**The Lancet**

Nov 18, 2023 Volume 402 Number 10415 p1805-1940

<https://www.thelancet.com/journals/lancet/issue/current>

[New issue; No digest content identified]

**The Lancet Child & Adolescent Health**

Nov 2023 Volume 7 Number 11 p747-814, e18-e20

<https://www.thelancet.com/journals/lanchi/issue/current>

[Reviewed earlier]

**Lancet Digital Health**

Nov 2023 Volume 5 Number 11 e749-e847

<https://www.thelancet.com/journals/landig/issue/current>

[Reviewed earlier]

## **Lancet Global Health**

Nov 2023 Volume 11 Number 11 e1667-e1826

<https://www.thelancet.com/journals/langlo/issue/current>

[Reviewed earlier]

## **Lancet Infectious Diseases**

Nov 2023 Volume 23 Number 11 p1207-1322, e455-e505

<https://www.thelancet.com/journals/laninf/issue/current>

[Reviewed earlier]

## **Lancet Public Health**

Nov 2023 Volume 8 Number 11 e827-e904

<https://www.thelancet.com/journals/lanpub/issue/current>

[Reviewed earlier]

## **Lancet Respiratory Medicine**

Nov 2023 Volume 11 Number 11 p945-1034, e89-e95

<https://www.thelancet.com/journals/lanres/issue/current>

*Editorial*

### **[Tuberculosis: setting achievable targets for elimination](#)**

The Lancet Respiratory Medicine

On Sept 22, 2023, the UN General Assembly held the second high-level meeting on the fight against tuberculosis. In the political declaration submitted by the President of the General Assembly, member states reaffirmed their collective commitment to end tuberculosis by 2030. Although previous pledges—including those made at the first UN high-level meeting in 2018—were followed by declining incidence and mortality, progress was unacceptably slow and was abruptly reversed by the COVID-19 pandemic. A plethora of tools and interventions is available to take important steps towards tuberculosis elimination, and possible paths to a tuberculosis-free world have been mapped out many times, yet 1·6 million people worldwide are estimated to have died from the disease in 2021. A burning question is how individual member states and key stakeholders can be held accountable and supported to ensure that progress towards elimination is achieved.

Tuberculosis is a preventable and curable disease. In high-income settings, rapid detection and appropriate drug treatment and adherence support are effective tools for tuberculosis control. However, decision makers in low-income and middle-income countries, where the disease remains a leading cause of death, are faced with the seemingly impossible task of making progress in the fight against tuberculosis when they are faced with a multitude of other priorities and often extremely limited resources. Sound investments and innovative solutions are needed to reduce the staggering health and economic costs of tuberculosis and post-tuberculosis sequelae for individuals, communities, societies, and countries.

The BCG vaccine, which has variable efficacy in adolescents and adults, is still the only tuberculosis vaccine licensed for use in humans. A phase 3 trial of M72/AS01 is planned (NCT06062238) and several other vaccine candidates are moving through the pipeline. The 78th session of the UN General Assembly saw the establishment of the WHO Tuberculosis Vaccine Accelerator Council, a voluntary network that aims to facilitate development, testing, authorisation, and delivery of new tuberculosis vaccines to those most in need.

A novel vaccine will be an important part of future efforts to eliminate tuberculosis, but practical action to end tuberculosis must not be delayed. Multisectoral approaches to combat poverty and address the social determinants of ill health, with steps to build stronger health systems and achieve universal health coverage, are undoubtedly important. Tuberculosis-specific policies, including a strengthening of tuberculosis services with improved access to affordable, high-quality diagnostic, preventive, and therapeutic tools, must also be prioritised and tailored to the needs of individual countries and communities. A focus on the implementation of existing strategies—with studies to support the implementation, at scale, of multicomponent approaches—must go hand in hand with efforts to develop new tools.

The past 5 years have seen many challenges and barriers to progress, and concerns about the changing face of tuberculosis have grown—from the threats posed by drug-resistant tuberculosis to the needs of populations affected by conflict, economic and political upheaval, or natural disasters. In a new report from the *Lancet Commission* on tuberculosis, the commissioners review progress made and roadblocks encountered since 2018, endorse a new set of tools to accelerate response efforts, and provide a revised assessment of investment priorities. They stress once again that political will and financial investments will be key to progress, and highlight the need for increased donor assistance for tuberculosis control efforts. Importantly, they point to COVID-19 as an example of what collective action can achieve against a global infectious disease threat.

Renewed commitment to ambitious, feasible long-term goals is a crucial step in the right direction, but will we see accelerated progress? A framework of accountability that focuses decision makers on tuberculosis within their political lifetimes could be key. In the *European Respiratory Journal*, Migliori and colleagues propose a new approach to target setting for tuberculosis elimination. They present a framework with five stages: high incidence, moderate incidence, low incidence, nearing pre-elimination, and pre-elimination. Each stage has a 5-year incidence target, with a list of priority actions and key tuberculosis-specific interventions to allow countries to take achievable steps—from stage to stage—towards elimination. The hope is that elimination will remain an aspirational goal for all countries, and that achievable near-term targets, with clear priorities for all partners, will allow gains to be made for which individual countries and key stakeholders can be held accountable.

#### *Articles*

**[Efficacy of a bivalent \(D614 + B.1.351\) SARS-CoV-2 recombinant protein vaccine with AS03 adjuvant in adults: a phase 3, parallel, randomised, modified double-blind, placebo-controlled trial](#)**

Gustavo H Dayan, et al. on behalf of the VAT00008 Study Team

#### **Maternal and Child Health Journal**

Volume 27, issue 12, December 2023

<https://link.springer.com/journal/10995/volumes-and-issues/27-12>

[New issue; No digest content identified]

#### **Medical Decision Making (MDM)**

Volume 43 Issue 7-8, October-November 2023

<http://mdm.sagepub.com/content/current>

[Reviewed earlier]

#### **The Milbank Quarterly**

*A Multidisciplinary Journal of Population Health and Health Policy*

Volume 101, Issue 3 Pages: 637-998 September 2023

<https://onlinelibrary.wiley.com/toc/14680009/current>

[Reviewed earlier]

### **Molecular Therapy**

Nov 01, 2023 Volume 31 Issue 11 p3105-3356

<https://www.cell.com/molecular-therapy/current>

[Reviewed earlier]

### **Nature**

Volume 623 Issue 7987, 16 November 2023

<https://www.nature.com/nature/volumes/622/issues/7987>

*World View* 15 Nov 2023

#### **[Yes to global standards for research — as long as they are truly global](#)**

Guidelines for research can level the playing field for scientists in low-resource settings — but diverse voices are needed to ensure that people worldwide can actually follow them.

Maneesha S. Inamdar

*Article* 01 Nov 2023

#### **[Historical narratives about the COVID-19 pandemic are motivationally biased](#)**

How people remember various aspects of the COVID-19 pandemic, including their own behaviour, perception of risk and attitudes towards science and governmental policies, is biased by their perceptions and behaviour today.

Philipp Sprengholz, Luca Henkel, Cornelia Betsch

### **Nature Biotechnology**

Volume 41 Issue 11, November 2023

<https://www.nature.com/nbt/volumes/41/issues/11>

[New issue; No digest content identified]

### **Nature Communications**

<https://www.nature.com/subjects/health-sciences/ncomms>

(Accessed 18 Nov 2023)

[No new digest content identified]

### **Nature Genetics**

Volume 55 Issue 11, November 2023

<https://www.nature.com/ng/volumes/55/issues/11>

[New issue; No digest content identified]

### **Nature Human Behaviour**

Volume 7 Issue 10, October 2023

<https://www.nature.com/nathumbehav/volumes/7/issues/10>

[Reviewed earlier]

## **Nature Medicine**

Volume 29 Issue 10, October 2023

<https://www.nature.com/nm/volumes/29/issues/10>

[Reviewed earlier]

## **Nature Reviews Drug Discovery**

Volume 22 Issue 11, November 2023

<https://www.nature.com/nrd/volumes/22/issues/11>

*Comment* 08 Sept 2023

### **Defining rare conditions in the era of personalized medicine**

The total number of rare conditions is debated, partly because of the variety of definitions of what constitutes rare. A broader consensus view of what rare means, based on improved understanding of individual group and patient clinicopathological characteristics, will help maximize the impact of technological advances in therapeutic development programmes.

Daniel J. O'Connor, Michela Gabaldo, Anneliene Hechtelt Jonker

*Review Article* 18 Sept 2023

### **Drug delivery systems for CRISPR-based genome editors**

CRISPR-based genome editing has the potential to treat many human genetic diseases, but achieving stable, efficient and safe in vivo delivery remains a challenge. This Review assesses current delivery systems for genome editors—focusing on adeno-associated viruses and lipid nanoparticles—and highlights data from recent clinical trials. Emerging delivery systems and ongoing challenges in the field are discussed.

Victoria Madigan, Feng Zhang, James E. Dahlman

*Review Article* 11 Sept 2023

### **Artificial intelligence for natural product drug discovery**

Advances in computational omics technologies are enabling access to the hidden diversity of natural products, and artificial intelligence approaches are facilitating key steps in harnessing the therapeutic potential of such compounds, including biological activity prediction. This article discusses synergies between these fields to effectively identify drug candidates from the plethora of molecules produced by nature, and how to address the challenges in realizing the potential of these synergies.

Michael W. Mullooney, Katherine R. Duncan, Marnix H. Medem

## **Nature Reviews Genetics**

Volume 24 Issue 11, November 2023

<https://www.nature.com/nrg/volumes/24/issues/11>

*Review Article* 29 Jun 2023

### **Genomic newborn screening for rare diseases**

In this Review, the authors summarize the current evidence for the use of genomic sequencing in newborn screening for rare diseases. As several large-scale studies launch internationally, the authors discuss major challenges and opportunities that lie ahead and identify key research priorities.

Zornitza Stark, Richard H. Scott

## **Nature Reviews Immunology**

Volume 23 Issue 11, November 2023

<https://www.nature.com/nri/volumes/23/issues/11>



*Tools of the Trade* 06 Oct 2023

### **[Human immune organoids: a tool to study vaccine responses](#)**

In this Tools of the Trade article, Lisa Wagar (while in the Mark Davis lab) developed an in vitro immune organoid system from primary human lymphoid tissue that recapitulates productive adaptive immune responses.

Lisa E. Wagar

*Review Article* 24 Apr 2023

### **[The unique properties of IgG4 and its roles in health and disease](#)**

IgG4 has unique functional characteristics that are increasingly recognized to have a pathogenic role in autoimmunity, tumour immunology, IgG4-related diseases and anti-biologic responses, as well as a beneficial role in allergy and parasitic infections.

Theo Rispens, Maartje G. Huijbers

## **New England Journal of Medicine**

November 16, 2023 Vol. 389 No. 20

<https://www.nejm.org/toc/nejm/medical-journal>

[New issue; No digest content identified]

## **njp Vaccines**

<https://www.nature.com/njpvaccines/>

[Accessed 18 Nov 2023]

[No new digest content identified]

## **Pediatrics**

Volume 152, Issue 4 October 2023

<https://publications.aap.org/pediatrics/issue/152/4>

[Reviewed earlier]

## **PharmacoEconomics**

Volume 41, issue 11, November 2023

<https://link.springer.com/journal/40273/volumes-and-issues/41-11>

[Reviewed earlier]

## **PLoS Biology**

<https://journals.plos.org/plosbiology/>

(Accessed 18 Nov 2023)

[No new digest content identified]

## **PLoS Genetics**

<https://journals.plos.org/plosgenetics/>

(Accessed 18 Nov 2023)

[No new digest content identified]

## **PLoS Global Public Health**

[https://journals.plos.org/globalpublichealth/search?sortOrder=DATE\\_NEWEST\\_FIRST&filterStartDate=2021-10-01&filterJournals=PLOGlobalPublicHealth&q=&resultsPerPage=60](https://journals.plos.org/globalpublichealth/search?sortOrder=DATE_NEWEST_FIRST&filterStartDate=2021-10-01&filterJournals=PLOGlobalPublicHealth&q=&resultsPerPage=60)

(Accessed 18 Nov 2023)

[No new digest content identified]

### **PLoS Medicine**

<http://www.plosmedicine.org/>

(Accessed 18 Nov 2023)

[No new digest content identified]

### **PLoS Neglected Tropical Diseases**

<http://www.plosntds.org/>

(Accessed 18 Nov 2023)

[No new digest content identified]

### **PLoS One**

<http://www.plosone.org/>

[Accessed 18 Nov 2023]

#### **[Trend analysis of COVID-19 mis/disinformation narratives—A 3-year study](#)**

Bonka Kotseva, Irene Vianini, Nikolaos Nikolaidis, Nicolò Faggiani, Kristina Potapova, Caroline Gasparro, Yaniv Steiner, Jessica Scornavacche, Guillaume Jacquet, Vlad Dragu, Leonida della Rocca, Stefano Bucci, Aldo Podavini, Marco Verile, Charles Macmillan, Jens P. Linge

Research Article | published 17 Nov 2023 PLOS ONE

<https://doi.org/10.1371/journal.pone.0291423>

### **PLoS Pathogens**

<http://journals.plos.org/plospathogens/>

[Accessed 18 Nov 2023]

[No new digest content identified]

### **PNAS - Proceedings of the National Academy of Sciences of the United States**

November 14, 2023 vol. 120 no. 46

<https://www.pnas.org/toc/pnas/120/46>

[New issue; No digest content identified]

### **PNAS Nexus**

Volume 2, Issue 10, October 2023

<https://academic.oup.com/pnasnexus/issue/2/10>

[New issue; No digest content identified]

### **Prehospital & Disaster Medicine**

Volume 38 - Issue 5 - October 2023

<https://www.cambridge.org/core/journals/prehospital-and-disaster-medicine/latest-issue>

[Reviewed earlier]

## **Preventive Medicine**

Volume 174 September 2023

<https://www.sciencedirect.com/journal/preventive-medicine/vol/174/suppl/C>

[Reviewed earlier]

## **Proceedings of the Royal Society B**

29 November 2023 Volume 290 Issue 2011

<https://royalsocietypublishing.org/toc/rspb/current>

[New issue; No digest content identified]

## **Public Health**

Volume 223 Pages e1-e16, 1-256 (October 2023)

<https://www.sciencedirect.com/journal/public-health/vol/223/suppl/C>

[Reviewed earlier]

## **Public Health Ethics**

Volume 16, Issue 2, July 2023

<http://phe.oxfordjournals.org/content/current>

[Reviewed earlier]

## **Public Health Genomics**

2023, Vol. 26, No. 1

<https://karger.com/phg/issue/26/1>

[Reviewed earlier]

## **Public Health Reports**

Volume 138 Issue 5, September/October 2023

<https://journals.sagepub.com/toc/phrg/138/5>

[Reviewed earlier]

## **Qualitative Health Research**

Volume 33 Issue 13, November 2023

<https://journals.sagepub.com/toc/QHR/current>

*Open Access Research article*

First published September 5, 2023pp. 1177–1188

### **[Protecting Personhood: A Classic Grounded Theory](#)**

Amélia Didier, et al.

*Abstract*

The importance of perceiving and considering patients as healthcare partners has been increasingly promoted. Healthcare systems around the world are now highly interested in patient engagement, participation, collaboration, and partnership. Healthcare ...

## **Research Ethics**

Volume 19 Issue 4, October 2023

<http://journals.sagepub.com/toc/reab/current>

[Reviewed earlier]

### **Reproductive Health**

<http://www.reproductive-health-journal.com/content>

[Accessed 18 Nov 2023]

[No new digest content identified]

### **Revista Panamericana de Salud Pública/Pan American Journal of Public Health (RPSP/PAJPH)**

<https://www.paho.org/journal/en>

15 Nov 2023

[Digital transformation as a strategy to strengthen essential public health functions in the Americas](#)

*Special report* | Spanish |

### **Risk Analysis**

Volume 43, Issue 11 Pages: 2147-2399 November 2023

<https://onlinelibrary.wiley.com/toc/15396924/current>

[New issue; No digest content identified]

### **Risk Management and Healthcare Policy**

<https://www.dovepress.com/risk-management-and-healthcare-policy-archive56>

[Accessed 18 Nov 2023]

[Reviewed earlier]

### **Science**

Volume 382| Issue 6672| 17 Nov 2023

<https://www.science.org/toc/science/current>

[New issue; No digest content identified]

### **Science and Engineering Ethics**

Volume 29, issue 5, October 2023

<https://link.springer.com/journal/11948/volumes-and-issues/29-5>

[Reviewed earlier]

### **Science Translational Medicine**

Volume 15| Issue 722| 15 Nov 2023

<https://www.science.org/toc/stm/current>

*Research Articles*

[Effects of boosting and waning in highly exposed populations on dengue epidemic dynamics](#)

BY Rosemary A. Aogo, et al.

15 Nov 2023

Antibody boosting and decay in highly immune individuals shape dengue epidemic dynamics, suggesting that repeat exposure helps maintain protection.

### **Scientific Reports**

<https://www.nature.com/srep/articles?type=article>

[Accessed 18 Nov 2023]

[No new digest content identified]

### **Social Science & Medicine**

Volume 332 September 2023

<https://www.sciencedirect.com/journal/social-science-and-medicine/vol/332/suppl/C>

[Reviewed earlier]

### **Systematic Reviews**

<https://systematicreviewsjournal.biomedcentral.com/articles>

[Accessed 18 Nov 2023]

[No new digest content identified]

### **Theoretical Medicine and Bioethics**

Volume 44, issue 5, October 2023

<https://link.springer.com/journal/11017/volumes-and-issues/44-5>

[Reviewed earlier]

### **Travel Medicine and Infectious Diseases**

Volume 55 September–October 2023

<https://www.sciencedirect.com/journal/travel-medicine-and-infectious-disease/vol/55/suppl/C>

[Reviewed earlier]

### **Tropical Medicine & International Health**

Volume 28, Issue 10 Pages: i-iv, 797-838 October 2023

<https://onlinelibrary.wiley.com/toc/13653156/current>

[Reviewed earlier]

### **Vaccine**

Volume 41, Issue 47 Pages 6895-7034 (13 November 2023)

<https://www.sciencedirect.com/journal/vaccine/vol/41/issue/47>

*Publication website not responding at inquiry.*

### **Vaccines**

<https://www.mdpi.com/journal/vaccines>

[Accessed 18 Nov 2023]

*Latest Articles [Selected]*

*Open Access Article*

## [Safety, Tolerability, and Immunogenicity of Measles and Rubella Vaccine Delivered with a High-Density Microarray Patch: Results from a Randomized, Partially Double-Blinded, Placebo-Controlled Phase I Clinical Trial](#)

by Ben Baker

Vaccines 2023, 11(11), 1725; <https://doi.org/10.3390/vaccines11111725> - 17 Nov 2023

### *Abstract*

Microarray patches (MAPs) have the potential to be a safer, more acceptable, easier-to-use, and more cost-effective means for the administration of vaccines than injection by needle and syringe. Here, we report findings from a randomized, partially double-blinded, placebo-controlled Phase I trial using the [...]

*Open Access Article*

## [New Vaccine Introductions in WHO African Region between 2000 and 2022](#)

by [Chinwe Iwu-Jaja](#), et al.

Vaccines 2023, 11(11), 1722; <https://doi.org/10.3390/vaccines11111722> - 16 Nov 2023

### *Abstract*

Significant progress has been made in vaccine development worldwide. This study examined the WHO African Region's vaccine introduction trends from 2000 to 2022, excluding COVID-19 vaccines. We extracted data on vaccine introductions from the WHO/UNICEF joint reporting form for 17 vaccines. We examined...

## **Value in Health**

November 2023 Volume 26 Issue 11p1581-1674

<https://www.valueinhealthjournal.com/current>

[Reviewed earlier]

.....  
.....

### ***Contents [click to move among sections]***

:: [Milestones, Perspectives](#)

:: [WHO](#)

:: [Organization Announcements](#)

:: [Journal Watch](#)

:: [Pre-Print Servers](#)

.....  
.....

## ***Pre-Print Servers***

### **Gates Open Research**

<https://gatesopenresearch.org/browse/articles>

[Accessed 18 Nov 2023]

*Selected Research*

*No new digest content identified.*

### **medRxiv**

<https://www.medrxiv.org/content/about-medrxiv>

[Accessed 18 Nov 2023]

*[Filter: All articles]*

### *Selected Research*

#### **Potential impact of annual vaccination with reformulated COVID-19 vaccines: lessons from the U.S. COVID-19 Scenario Modeling Hub**

Sung-mok Jung, Sara L Loo, Emily Howerton, Lucie Contamin, Claire P Smith, Erica C Carcelén, Katie Yan, Samantha J Bents, Jessi Espino, John Levander, Joseph C Lemaitre, Koji Sato, Clifton D McKee, Alison L Hill, Matteo Chinazzi, Jessica T Davis, Kunpeng Mu, Alessandro Vespignani, Erik T Rosenstrom, Sebastian A Rodriguez-Cartes, Julie S Ivy, Maria E Mayorga, Julie L Swann, Guido España, Sean Cavany, Sean M Moore, Alex Perkins, Shi Chen, Rajib Paul, Daniel Janies, Jean-Claude Thill, Ajitesh Srivastava, Majd Al Aawar, Kaiming Bi, Shraddha Ramdas Bandekar, Anass Bouchnita, Spencer J Fox, Lauren Ancel Meyers, Przemyslaw Porebski, Srinivasan Venkatramanan, Aniruddha Adiga, Bryan Lewis, Brian Klahn, Benjamin Hurt, Jiangzhuo Chen, Amanda Wilson, Stefan Hoops, Parantapa Bhattacharya, Dustin Machi, Joseph Outten, Henning Mortveit, Anil Vullikanti, Madhav Marathe, Harry Hochheiser, Michael C Runge, Katriona Shea, Shaun Truelove, Cécile Viboud, Justin Lessler

medRxiv 2023.10.26.23297581; doi: <https://doi.org/10.1101/2023.10.26.23297581> Revision

#### **75 years journey of malaria publications: what and where?**

Nimita Deora, Sonlaika Kar, Veena Pande, Abhinav Sinha

edRxiv 2023.11.15.23298567; doi: <https://doi.org/10.1101/2023.11.15.23298567>

Background: Malaria is a life-threatening and ancient disease that has inflicted serious morbidity and mortality across the globe. The major brunt of the disease has been on African, South East Asian and South American countries. Proportionally, malaria has attracted global research priorities amongst infectious diseases and this is evident from the number of publications directly or indirectly related to malaria from across the globe, irrespective of the endemicity of the disease. However, formal and exhaustive analyses of these malaria publications are rarely done and published.

### **OSF Pre-prints**

<https://osf.io/preprints/discover?provider=OSF&subject=bepress%7CLife%20Sciences>

[Provider Filter: OSF Pre-prints Subject filters: Arts & Humanities; Education, Life Sciences; Medicine and Health Sciences; Social and Behavioral Sciences]

***We observe increasing levels of "posting pollution" by individuals, sometimes posting 10+ items of no value. We will resume selective monitoring beginning in September.***

### **Wellcome Open Research**

<https://wellcomeopenresearch.org/browse/articles>

[Accessed 18 Nov 2023]

*Selected Research*

*No new digest content identified.*

\* \* \* \*

### **Think Tanks**

**Brookings** [to 18 Nov 2023]

<http://www.brookings.edu/>

*Research*

*No new digest content identified.*

**Center for Global Development** [to 18 Nov 2023]

<https://www.cgdev.org/>

*All Research [Selected]*

*WORKING PAPERS*

**[Estimated Future Mortality from Pathogens of Epidemic and Pandemic Potential](#)**

Nita K. Madhav et al.

November 13, 2023

**Chatham House** [to 18 Nov 2023]

<https://www.chathamhouse.org/>

*Selected Analysis, Comment, Events*

*No new digest content identified.*

**Council on Foreign Relations** [to 18 Nov 2023]

<https://www.cfr.org/media/news-releases>

*New Releases [Selected]*

*No new digest content identified.*

**CSIS** [to 18 Nov 2023]

<https://www.csis.org/>

*Reports [Selected]*

*No new digest content identified.*

**Kaiser Family Foundation** [to 18 Nov 2023]

[https://www.kff.org/search/?post\\_type=press-release](https://www.kff.org/search/?post_type=press-release)

*Newsroom*

**[Most Black and Hispanic Adults Expect to Get the New COVID-19 Vaccine, Though Most White Adults Don't](#)**

November 17, 2023 News Release

The latest KFF COVID-19 Vaccine Monitor survey reveals that half (51%) of all adults nationally say they “definitely” or “probably” will not get the latest COVID-19 vaccine, with many saying that they aren’t worried about catching the virus. One in five (20%) say that they’ve already gotten the new vaccine...

**McKinsey Global Institute** [to 18 Nov 2023]

<https://www.mckinsey.com/mgi/overview>

*Latest Research*

*No new digest content identified.*

**ODI [Overseas Development Institute]** [to 18 Nov 2023]

<https://odi.org/en/publications/>

*Publications [Selected]*

**[Navigating fragility: the new multilateral agenda](#)**

17 November 2023

Briefing/policy papers



**Pew Research Center** [to 18 Nov 2023]

<https://www.pewresearch.org/>

*Latest Publications [Selected]*

*Report* | Nov 14, 2023

### **[Americans' Trust in Scientists, Positive Views of Science Continue to Decline](#)**

The share of Americans who say science has had a mostly positive impact on society has fallen 16 percentage points since before the start of the coronavirus outbreak, from 73% in January 2019 to 57% today.

**Rand** [to 18 Nov 2023]

<https://www.rand.org/pubs.html>

*Published Research [Selected]*

*Report*

### **[Data collection and sharing for pathogen surveillance: Making sense of a fragmented global system](#)**

Study providing an overview of the pathogen surveillance space, involved stakeholders, strengths and weaknesses of initiatives, challenges of pathogen surveillance, and how data has been used to inform public health decision making.

Nov 15, 2023

Sarah Parkinson, Jessica Dawney, Avery Adams, Ben Senator

**Urban Institute** [to 18 Nov 2023]

<https://www.urban.org/publications>

### **[New Research Publications - Selected](#)**

**World Economic Forum** [to 18 Nov 2023]

<https://agenda.weforum.org/press/>

*Media*

### **[Global Leaders Advance Responsible AI Development at Governance Summit](#)**

News 17 Nov 2023

- More than 200 leaders came together at the World Economic Forum's AI Governance Summit to promote the responsible development and deployment of generative artificial intelligence
- Participants called for the establishment of a robust international AI governance framework.
- Topics of discussion included the importance of closing the digital divide and trade-offs in open-source technology.
- Learn more about the AI Governance Alliance [here](#).

.....

.....

## **Public Consultations/Call for Papers**

### **[Call for Contributions - OHCHR analytical study on key challenges in ensuring access to medicines, vaccines and other health products \(HRC resolution 50/13\)](#)**

*Office of the High Commissioner for Human Rights | Call for input | Treaty bodies*

**Deadline: 30 November 2023**

*Purpose:*

To inform the OHCHR analytical study on key challenges in ensuring access to medicines, vaccines and other health products (HRC resolution 50/13)

*Background:*

Vaccine equity and access to medicines is a fundamental component of the full realization of the right to health. Vaccines, medicines and other health products must not only be produced and made available - they must also be accessible to all persons. Yet, access to vaccines, medicines and other health products remains disturbingly uneven in many places.

Council resolution 50/13 requests the Office of the High Commissioner for Human Rights (OHCHR) to prepare an analytical study on key challenges in ensuring access to medicines, vaccines and other health products to be presented to the Human Rights Council at the fifty-sixth session in June 2024. In order to collect inputs for this forthcoming report, OHCHR has published a short questionnaire available in English, Français and Español.

\* \* \* \* \*  
\* \* \* \* \*

***Vaccines and Global Health: The Week in Review*** is a service of the Center for Vaccine Ethics and Policy (CVEP) / GE2P2 Global Foundation, which is solely responsible for its content.

.....

*Copyright GE2P2 Global Foundation 2023. Some Rights Reserved.*

*This work is licensed under the Creative Commons Attribution 4.0 International License. To view a copy of this license, visit <http://creativecommons.org/licenses/by/4.0/> or send a letter to Creative Commons, PO Box 1866, Mountain View, CA 94042, USA.*

*Under the terms of this license, you may copy, redistribute, and adapt the work for non-commercial purposes, provided the work is appropriately cited, as indicated below. In any use of this work, there should be no suggestion that the GE2P2 Global Foundation endorses any specific organization, products, or services. The use of the GE2P2 Global Foundation logo is not permitted. If you adapt the work, then you must license your work under the same or equivalent Creative Commons license.*

.....

CVEP is a program of the GE2P2 Global Foundation whose purpose and mission is to advance ethical and scientific rigor in research and evidence generation for governance, policy and practice in health, human rights action, humanitarian response, heritage stewardship, education and sustainable development. The Foundation serves governments, international agencies, INGOs, civil society organizations (CSOs), commercial entities, consortia and alliances.

Support for this service is provided by the Bill & Melinda Gates Foundation; the Bill & Melinda Gates Medical Research Institute, and industry resource members Janssen/J&J, Pfizer, Sanofi US, and Takeda, (list in formation).

Support is also provided by a growing list of individuals who use this membership service to support their roles in public health, clinical practice, government, NGOs and other international institutions, academia and research organizations, and industry.

\* \* \* \* \*

\*

\*

\*

\*